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SUMMARY 
Prion diseases are invariably lethal transmissible diseases for which no efficient 
treatment currently is available. These include in humans the sporadic form called 
sporadic Creutzfeld-Jakob Disease (sCJD), the iatrogenic form acquired upon 
transmission of prion infectious particles (iCJD), several heritable forms including 
Gerstmann-Sträussler-Scheinker syndrome (GSS) and Fatal Familial Insomnia (FFI), 
the Papua New Guinea-endemic Kuru and the BSE-derived form new variant CJD 
(nvCJD). The normal prion protein, termed PrPC, for which no physiological function 
has been yet convincingly demonstrated is coded by the gene Prnp and happens to be 
converted into a misfolded form, termed PrPSc, which can be transmitted, for example 
through blood donation. In addition, several conformational isoforms of PrPSc are 
possible, yielding the puzzling phenomenon called “prion strains”. In addition, several 
cell and tissue culture assays enable the determination of infectivity titer of tissue 
samples. Finally, naturally- or experimentally-occurring prion deposits characterizing 
different prion strains can be discriminated in tissue sections by using novel 
molecules called luminescent conjugated polymers (LCPs). In particular, 
polythiophene acetic acid (PTAA) has been used to unravel conformational variants 
of the mouse prion protein in animals infected with several mouse-adapted prion 
strains. 
 
The strong interaction of LCPs with prion aggregates and amyloid structures related 
to various amyloid-involving diseases provides the rationale for testing their potential 
antiprion effect. In the first part of my thesis I show that incubation with anionic, 
cationic or zwitterionic LCPs not only depleted the infectivity of a prion-containing 
brain homogenate but also limited prion accumulation in cerebellar organotypic 
cultured slices (COCS). In addition, by using several techniques for quantifying prion 
content, I link decreased infectivity with structural changes of prion aggregates. 
Surprisingly, I could show that PrPSc resistance to proteolysis was enhanced and LCP-
treated recombinant mPrP23-231 fibers were visualized as more compact aggregates 
that were also more stable to proteolysis. These results suggest that LCPs exert their 
antiprion effect by rendering PrP aggregates more compact, which may prevent 
release of infectious prion seeds. In addition, ELISA on COCS as well as a conversion 
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assay using recombinant mPrP23-231 show that PTAA may also prevent the transition 
of PrPC to PrPSc by interacting with PrPC or an intermediate molecular variant. 
I therefore propose LCPs as a new class of antiprion compounds that prevent 
propagation of prion infectious species by enhancing compactness of PrPSc deposits. 
 
In the second part of my thesis I describe the development of a method for using 
LCPs as a tool to study phenomena related to prion strains in COCS, such as prion 
strain adaptation and prion strain competition. LCPs have previously been proven to 
be powerful tools to investigate the structure of PrPSc aggregates linked with different 
prion strains. Here I propose to combine the use of these molecules with the prion 
organotypic slice culture assay to study prion strains in a fast manner: Indeed, prion 
propagation in COCS enables analysis of amyloid aggregates that are readily stainable 
and observable in COCS after already five weeks, versus several months in mice. 
Notably, I could reproduce the results previously obtained by C. J. Sigurdson and K. 
P. R. Nilsson in mice in a very fast manner in COCS. 
 
In the third part of my thesis I describe collaborative work that has led to the 
identification of human stem cell-reconstituted Prnp knockout mice as a bioreactor for 
human prions. In particular, I have shown that these mice had efficiently replicated 
CJD prions. 
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ZUSAMMENFASSUNG 
Prionenerkrankungen sind ausnahmslos letale übertragbare Erkrankungen, für die 
keine effiziente Behandlung zur Verfügung steht. Zu diesen Erkrankungen gehören 
die sogenannte Creutzfeld-Jakob Erkrankung (sCJD), die iatronische Form (iCJD), die 
durch die Übertragung von infektiösen Prionenpartiklen erworben wird, sowie 
mehrere erbliche Formen, wie z.B. das Gerstmann-Sträussler-Scheinker-Syndrome 
(GSS) und die familiäre fatale Insomnie (FFI), die in Papua-Neuguinea auftretende 
endemische Erkrankung Kuru und die durch BSE-übertragene neue Variante der CJD 
(nvCJD). Die normale Form des Prionproteins, PrPC, für das noch keine 
physiologische Funktion überzeugend beschrieben worden ist, wird von dem Gen 
Prnp kodiert und kann in eine falschgefaltete Form, PrPSc, umgewandelt werden, 
welche übertragbar ist, z.B. bei der Blutspende. Weiterhin kann PrPSc verschiedene 
konformationelle Isoformen annehmen, was zu dem Auftreten des verwirrenden 
Phänomens verschiedener Prionenstämme geführt hat. Die Infektiösität von Prionen-
infizierten Gewebeproben kann mittels verschiedenen Zell- und 
Gewebekulturuntersuchungen bestimmt werden. Schlussendlich, natürliche und 
experimentell-auftretende Prionenablagerungen verschiedener Prionenstämme können 
in Gewebeschnitten mittels neuer Moleküle, welche als “luminescent conjugated 
polymers (LCPs)“ bezeichnet, unterschieden werden. Namentlich, “polythiophene” 
Essigsäure (PTAA) wurde zur Unterscheidung von verschiedenen konformationellen 
Varianten des Mausprionproteins von Tieren, welche mit verschieden Maus-
adaptierten Prionenstämmen infiziert wurden, verwendet.  
 
Die starke Wechselwirkung von LCPs mit Prionenaggregaten und Amyloidstrukturen, 
die mit verschiedenen Amyloid-Erkrankungen in Verbindung gebracht werden, hat 
die Untersuchung von LCPs auf deren Anti-Prionen-Effekt nahegelegt. Im ersten Teil 
meiner Arbeit zeige ich, dass die Inkubation mit verschiedenen LCPs, darunter 
anionische, kationische und zwitterionische, die Infektiosität von prioneninfiziertem 
Hirnhomogenat senkte und die Prionenaggregation in zerebellaren organotypischen 
kultivierten Hirnscheiben (COCS)  hemmte. Unter Anwendung diverser Techniken 
zur Quantifizierung des Prionengehalts konnte ich einen Zusammenhang zwischen der 
verminderten Infektiosität und der strukturellen Veränderungen der Prionenaggregate 
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zeigen. Überraschenderweise zeigte sich, dass die Resistenz von PrPSc gegenüber 
Proteolyse wuchs und LCP-behandelte rekombinante mPrP23-231 Fasern kompaktere 
Aggregate bildeten, die ebenfalls resistenter gegenüber Proteolyse waren. Diese 
Befunde legen nahe, dass die LCPs ihren Anti-Prionen-Effekt erzielen, indem sie PrP-
Aggregate kompakter machen, und somit die Freisetzung von infektiösen Keimen 
verhindern. Darüber hinaus zeigen ELISA-Daten der COCS sowie 
Konvertierungsexperimente mit rekombinantem mPrP23-231, dass PTAA 
möglicherweise auch die Umwandlung von PrPC in PrPSc durch Wechselwirkung mit 
PrPC oder einem molekularen Zwischenprodukt verhindert. Ich schlage deshalb vor, 
dass LCPs eine neue Klasse von Anti-Prionen-Verbindungen darstellen, die die 
Ausbreitung von prioneninfiziertem Partikeln verhindert, in dem sie die Kompaktheit 
von PrPSc-Ablagerungen erhöhen. 
 
Im zweiten Teil meiner Arbeit beschreibe ich die Entwicklung einer Methode, die es 
ermöglicht, LCPs einzusetzen, um Phänomene im Zusammenhang mit 
Prionenstämmen in COCS zu beobachten, wie z.B. Prionenstamm Kompetition und 
Prionenstamm Anpassung. Vor kurzem konnte gezeigt werden, dass LCPs gut 
geeignet sind, um die Struktur von PrPSc-Aggregaten in Verbindung mit 
verschiedenen Prionenstämmen zu untersuchen. Ich zeige auf, dass die Verwendung 
dieser Moleküle kombiniert mit einem Prion organotypischen Kokultur-Assay die 
Untersuchung von Prionenstämmen vereinfacht: Prionvermehrung in COCS erlaubt 
die Analyse von Amyloidaggregaten, die bereits gefärbt und beobachtet werden 
können,  in COCS schon nach fünf Wochen versus mehrere Monate in Mäusen. Ich 
konnte vorgängige Resultate von C. J. Sigurdson and K. P. R. Nilsson in Mäusen auf 
diese Weise in sehr kurzer Zeit reproduzieren. 
 
Der dritte Teil meiner Arbeit beschreibt eine Zusammenarbeit, die zur Identifikation 
von mit menschlichen Stammzellen rekonstituierten Prnp Knockout-Mäusen als 
Bioreaktor für menschliche Prionen geführt hat. Insbesondere konnte ich zeigen, dass 
diese Mäuse CJD Prionen sehr effizient replizierten.
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DEFINITIONS 
Prion: Agent of transmissible spongiform encephalopathy (Khoor et al.), with 
unconventional properties. The term does not have structural implications other than 
that a protein is an essential component. 
 
'Protein-only' hypothesis: Maintains that the prion is devoid of informational nucleic 
acid, and that the essential pathogenic component is protein (or glycoprotein). Genetic 
evidence indicates that the protein is an abnormal form of PrP (perhaps identical with 
PrPSc). The association with other 'non-informational' molecules (such as 
glycosaminoglycans, or maybe even short nucleic acids) is not excluded. 
 
PrPC: The naturally occurring form of the mature Prnp gene product. Its presence in a 
given cell type is necessary, but not sufficient, for replication of the prion. 
 
PrPSc: An 'abnormal' form of the mature Prnp gene product found in tissue of TSE 
sufferers, defined as being partly resistant to digestion by proteinase K (PK) under 
standardized conditions. It is believed to differ from PrPC only (or mainly) 
conformationally, and is often considered to be the transmissible agent or prion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Aguzzi and Weissmann (Aguzzi and Weissmann, 1997)
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ABBREVIATIONS 
BBB Blood-brain barrier 
BH Brain homogenate 
BSE Bovine spongiform encephalopathy 
CGN Cerebellar granule neuron 
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
COCS Cultured organotypic cerebellar slices 
COCSBH Brain homogenate prepared from COCS 
CR Congo red 
CWD Chronic wasting disease 
DPI Days post-inoculation 
DIV Days in vitro 
FFI Fatal familial insomnia 
GPI glycosylphosphatidylinositol 
GSS Gerstmann-Sträussler-Scheinker disease 
LCP Luminescent conjugated polythiophene 
MPA Misfolded protein assay 
PK Proteinase K 
POSCA Prion organotypic slice culture assay 
PPS Pentosan polysulfate 
PrPC Cellular prion protein 
PrPSc Scrapie-associated prion protein 
recPrP Recombinant PrP 
RML Rocky Mountain laboratory prion strain  
SDS Sodium dodecyl sulfate 
SCA Scrapie cell assay 
SCEPA Scrapie cell assay end point assay 
LogID50 Prion infectivity units 
TEM Transmission electron micrscopy 
TSE Transmissible spongiform encephalopathy 
vCJD Variant Creutzfeldt-Jakob disease 
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INTRODUCTION 
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES 
Prion diseases, also called transmissible spongiform encephalopathies (TSEs), are a large 
group of lethal neurodegenerative disorders affecting both humans and animals (Aguzzi, 
2006). These diseases share similarities on the epidemiologic, pathological and biochemical 
levels: TSE refers to the transmissibility of the disease and to the neuropathological feature of 
songiform vacuolation classically seen in the CNS of sick individuals. TSEs can be 
dominantly inherited (as a result of a mutation of the prion gene) or transmitted (by infection 
with prion infectious seeds). If a genetic or infectious transmission can be excluded, they are 
classified as sporadic. Independently of their origin, however, all TSE can be transmitted 
experimentally and are therefore regarded as infectious diseases. Although many similarities 
to other neurodegenerative protein misfolding diseases such as Alzheimer’s, Huntington’s and 
Parkinson’s disease have been described (DeArmond, 1993; Aguzzi and Haass, 2003), prion 
diseases distinguish themselves by their transmissibility. The transmitting agent, called prion 
(from proteinaceous infectious only), distinguishes itself from conventional bacterial or viral 
infectious agents by its resistance to usual sterilization means (high temperature, treatment 
with formaldehyde or UV irradiation) and by the unusually long incubation time of the 
associated disease. The prion seems to be devoid of informational nucleic acids (Alper et al., 
1966; Alper et al., 1967) and prion infectivity tends to associate with accumulation in the 
brain of PrP-scrapie (PrPSc), a proteinase-resistant isoform of the naturally occurring, 
physiological cellular protein termed PrPC (Chesebro et al., 1985; Oesch et al., 1985b; Basler 
et al., 1986). The notion that a protein might be the infectious agent causing TSEs was first 
proposed by Griffith (Griffith, 1967). This idea was later on supported by Stanley Prusiner 
who named this protein the prion protein (Prusiner, 1982). Major neuropathological hallmarks 
of TSEs are extensive spongiosis, neuronal cell loss in the CNS, gliosis (DeArmond, 1993), 
and deposition of amorphous PrP aggregates (amyloid plaques) (Bendheim et al., 1984; 
DeArmond et al., 1985; Aguzzi, 1996; Manuelidis et al., 1997). The accumulation in the brain 
of PrP aggregates and the transmissibility of the disease are the defining traits of TSEs. 
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Animal prion diseases 
The naturally occurring prion disease called Scrapie has been recognized in sheep and goats 
since the 18th century (Aguzzi, 2006) and was initially termed “tremblante” in French because 
of the quivering syndrome developed by sick animals. Several other widespread occurrences 
of TSEs have recently been observed in other wild or domesticated species of animals. 
Animal TSEs include sheep and goat Scrapie (Cuille and Chelle, 1939), the original animal 
TSE that has been recognized more than 200 years ago, but also transmissible mink 
encephalopathy (TME) (Marsh and Hadlow, 1992), chronic wasting disease (CWD) of mule 
deer and elk (Williams and Young, 1980), feline spongiform encephalopathy (FSE) (Pearson 
et al., 1991; Eiden et al., 2010) and bovine spongiform encephalopathy (BSE) (Wells et al., 
1987). The first cases of CWD, a prion disease of captive and free-ranging mule deer and elk, 
were reported in the late 1960s in Colorado. This newly recognized TSE is currently 
spreading across the American continent (Sigurdson and Aguzzi, 2007). The unidentified path 
of horizontal transmission is still preventing means of controlling this epidemic. In the UK, a 
previously unobserved neurological disease in cattle associated with pathologic changes in the 
brain that were similar to those characteristic of TSEs was first recognized in 1986. This new 
form of TSE, called BSE or more commonly “mad-cow disease”, rapidly developed into a 
worrying epidemic in the UK and in other European countries. BSE was possibly caused by 
transmission of sheep Scrapie to cattle through infected fodder prepared from carcasses of 
sacrificed animals (Wilesmith, 1988; Aguzzi and Weissmann, 1996). Another hypothesis for 
the origin of BSE is the possible contamination of feed prepared from cattle with BASE, a 
possibly atypical sporadic form of BSE (Capobianco et al., 2007). The transmissibility of BSE 
to various animal species, including humans, unlike previously known prion diseases such as 
sheep scrapie, has raised enormous public health concerns. Even though the routes for 
transmission of prions in Scrapie and CWD remain elusive, several possible routes of 
horizontal transmission have been recently described, such as nephritis-associated 
transmission through urine (Seeger et al., 2005), mastitis-associated transmission through 
milk (Ligios et al., 2005), as well as transmission through saliva (Mathiason et al., 2006). 
Furthermore, transmission of prion infectivity through olfactory routes has been recently 
demonstrated (Haybaeck et al., 2011). 
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Human prion diseases 
Human TSEs include familial, sporadic and variant Creutztfeldt-Jakob diseases (CJD) (Gibbs 
et al., 1968), Fatal Familial Insomnia (FFI) (Medori et al., 1992), Gerstmann-Sträussler-
Scheinker syndrome (GSS) (Gajdusek, 1977) and Kuru (Gajdusek et al., 1966). These 
diseases can be either genetically inherited (Mastrianni, 2010), acquired by transmission of 
prion infectivity (Weissmann et al., 2002; Aguzzi and Polymenidou, 2004a; Haybaeck et al., 
2011) or occur sporadically (Edgeworth et al., 2010) (Figure 1, adapted from: (Aguzzi and 
Calella, 2009)). 
 
 
 
 
 
 
 
 
 
 
Figure 1: Human prion diseases 
Adapted from: (Aguzzi and Calella, 2009). 
 
Sporadic CJD occurs with an equal incidence in men and women and accounts for 85% of 
human prion diseases. Its rate of occurrence worldwide is 1 to 3 cases per million inhabitants 
per year. The origin of sporadic CJD is unknown. Different hypothesis propose that sporadic 
CJD could be triggered as a rare event by spontaneous conversion of PrPC into disease-
associated PrPSc or by somatic Prnp mutations. A predisposition to the development of 
sporadic and acquired CJD results from homozygosity for the M allele at a common coding 
polymorphism at codon 129 of Prnp gene encoding either methionine or valine (Collinge et 
al., 1991; Palmer et al., 1991; Windl et al., 1996). Individuals that are homozygous for the V 
allele are more resistant to infection than heterozygous ones (Baker et al., 1991). The 
observation of a very long incubation period (up to 50 years) between the time of infection 
and the clinical manifestation of Kuru has led to the concept that this disease was caused by 
“slow viruses” (Collinge et al., 2006). About 15 % of human prion diseases are associated 
with autosomal dominant mutations in the Prnp gene. Most pathogenic mutations in Prnp are 
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thought to trigger an increased tendency of PrPC to convert into PrPSc, however not all 
disease-causing Prnp mutations are associated with PrPSc and infectivity. The discovery of a 
new form of CJD in the UK in 1996 was epidemiologically and experimentally linked to the 
widespread BSE epidemic in the early 1990s. Although it is not yet possible to estimate the 
extent of a potential vCJD epidemic, preliminary data indicate a significant dietary exposure 
to BSE-infected meat in the UK. Although it seems that the annual new cases of vCJD have 
peaked (Aguzzi et al., 2007), all patients suffering from vCJD so far were homozygous for 
methionine at codon 129 of Prnp. Experiments in mice expressing different isoforms of 
human PrPC show that valine at codon 129 of Prnp inhibits transmission of BSE whereas 
mice homozygous for methionine develop BSE rapidly. The fact that heterozygous mice show 
a delayed onset of disease, but still develop clinical disease nonetheless (Wadsworth et al., 
2004), raises the concern of a delayed vCJD outbreak in humans that are heterozygous at 
codon 129. In addition, transmission of vCJD through blood donation from a donor, who 
developed vCJD several years after donating blood, to multiple recipients was recently 
described (Llewelyn et al., 2004; Wroe et al., 2006). This represents the formal proof of 
efficient transmission of vCJD through blood. Although many different assays for sensitive 
detection of prions in blood are currently under development, the danger of propagation of 
vCJD through blood donation cannot, at the moment, be obviated (MacGregor and Prowse, 
2004). Therefore, research efforts to understand the molecular basis of prion diseases, 
understand the mechanisms underlying species barrier and interspecies transmission, improve 
methods of diagnosis, and develop therapeutic strategies for treatment and prevention of the 
disease have been intensified. 
PRION CONVERSION REACTION 
As prion diseases are associated with brain accumulation of PrPSc, prion research has largely 
focused on the transition from PrPC to PrPSc. These two molecules were found to share a 
similar amino acid structure and no known covalent modifications could differentiate them 
(Stahl et al., 1993). It is therefore generally accepted that PrPSc is a posttranslational 
derivative of PrPC that has acquired an alternative structure. The protein-only hypothesis 
proposes that the nature of the infectious entity responsible for the triggering of any prion 
disease consists mainly of PrPSc, an abnormally-folded, protease-resistant, β-sheet-rich 
isoform of the normal cellular prion protein, termed PrPC (Prusiner, 1991, 1998). This concept 
has been further precised by Charles Weissmann (Weissmann, 1991): the prion is an 
infectious protein that does not contain any informational nucleic acids, and that propagates 
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by recruitment and “autocatalytic” conformational conversion of the normal cellular prion 
protein PrPC into disease-associated PrPSc (Aguzzi et al., 2007). The resolution of the 3D 
structure by NMR of mouse (Riek et al., 1996a) and human PrP (Hosszu et al., 1999) and the 
development of newer techniques to study amyloids such as hydrogen/deuterium exchange 
(Lu et al., 2007) have provided useful information about a possible conversion mechanism: 
since PrPSc appears to have more β-sheet content than PrPC, it is proposed that non-covalent 
interactions between compatible nucleic acid strands in PrPC make this molecule tend towards 
the structural state of PrPSc. Furthermore, it is proposed that pathologic PrPSc may operate the 
template-promoted further conversion of PrPC. The structural transition is accompanied by 
profound changes in the physicochemical properties of the prion protein. While PrPC
 
is 
soluble in mild detergents and sensitive to proteinase K (PK) digestion, PrPSc
 
forms insoluble 
aggregates and is partially resistant to PK (Bolton et al., 1982; Oesch et al., 1985a; Meyer et 
al., 1986). Attempts to purify PrPSc by fractionation and correlating the mass of the purified 
protein complexes to the infectivity of the samples, indicates that the most infectious prion 
particle has a mass corresponding to 14-28 PrP molecules (Silveira et al., 2005). However, the 
failure to establish a high resolution of the structure of PrPSc has precluded a full 
understanding of the conversion process. Nevertheless, two hypotheses have been developed 
to explain the pathological refolding of PrPC into PrPSc. The “refolding model” postulates a 
template assisted mechanism where a strong kinetic energy barrier prevents PrPC to misfold 
spontaneously into PrPSc. Overcoming of the high energy barrier is possible in the presence of 
a misfolded PrPSc template, possibly with the help of a chaperone (Telling et al., 1995) or 
another type of molecule (Priola et al., 2003) (Figure 2A, adapted from: (Aguzzi and 
Polymenidou, 2004b)) . The second hypothesis, “the seeding model” proposes that PrPC and 
PrPSc are in a natural equilibrium privileging PrPC although bi-directional conversion of PrPC 
and PrPSc is possible spontaneously. Secondary exposure to exogenous PrPSc induces a 
nucleation-polymerisation process promoting stabilization of PrPSc and further recruitment of 
endogenous PrPC into a PrPSc conformation (Jarrett and Lansbury, 1993) (Figure 2B). 
Mutations in PrPC could predispose PrPC to aggregate in PrPSc by destabilizing its 
conformation. 
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Figure 2: Models for the Conversion of PrPC into PrPSc. Adapted from: (Aguzzi and Polymenidou, 2004b). 
(A) The “refolding” or template assistance model postulates an interaction between exogenously introduced 
PrPSc and endogenous PrPC, which is induced to transform itself into further PrPSc. A high energy barrier may 
prevent spontaneous conversion of PrPC into PrPSc. 
(B) The “seeding” or nucleation-polymerization model proposes that PrPC and PrPSc are in a reversible 
thermodynamic equilibrium. Only if several monomeric PrPSc molecules are mounted into a highly ordered seed, 
further monomeric PrPSc can be recruited and eventually aggregates to amyloid. Within such a crystal-like seed, 
PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the number of nuclei, which can recruit 
further PrPSc and thus results in apparent replication of the agent.  
PRION PATHOGENESIS 
The mechanisms of prion pathogenesis leading to glial activation, neuronal cell death and the 
associated spongiosis and clinical signs are not yet understood. Mice lacking PrPC do not 
show significant behavioral phenotype or signs of neurodegeneration (Büeler et al., 1992), 
suggesting that prion diseases are not caused by a PrPC-associated loss-of-function. In fact 
prion replication and clinical signs upon intracerebral inoculation with prions are not observed 
if no PrPC is present (Büeler et al., 1993), which clearly shows that PrPC expression is crucial 
for prion replication. However, the link between PrPSc accumulating outside the cells and the 
damage to surrounding tissue is missing. Brandner et al. investigated this question by 
transplanting wild-type and PrP overproducing neuroectodermal grafts into brains of PrP 
knockout mice (Brandner et al., 1996). After the mice were intracebrally inoculated with 
prions the grafts accumulated high levels of PrPSc and prion infectivity and the tissue 
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developed typical Scrapie pathogenesis-induced histopathological changes. The surrounding 
tissue, which was not expressing PrP, remained healthy despite substantial accumulation of 
PrPSc occurred, which shows that cytotoxicity of PrPSc needs target cells to express cellular 
PrPC by. This was more recently confirmed in mice expressing a secreted form of PrPC (‘GPI-
anchorless’: a secreted PrP molecule lacking the glycosylphosphatidylinositol-anchor (GPI)) 
(Chesebro et al., 2005): Prion-inoculated mice replicated PrPSc without developing 
histopathological changes, illustrating that PrP must be membrane-bound to exert cellular 
toxicity. In addition, early signs of prion pathogenesis such as spongiosis and behavioral 
symptoms can be reversed by conditionally removing PrPC selectively in neurons after disease 
onset (Mallucci et al., 2003; Mallucci GR, 2007). Altogether this suggests that prion 
replication at the cell level could be a target for anti-prion intervention strategies. 
THE PRION STRAIN PHENOMENON 
Prion strains are defined by different disease phenotypes in identical hosts, such as incubation 
times, histological lesion profiles, organ-tropism, biophysical and biochemical features and 
targeted cells (Aguzzi et al., 2007). Circumstantial evidence points toward strain-specific 
properties being defined by different conformations of PrPSc present in the inoculum. The 
different stability against chaotropic salts and heat (Safar et al., 1998) and susceptibility to 
digestion with proteinase K (PK) of PrPSc isolates derived from different prion strains support 
this view: PrPSc tertiary structure defines resistance to denaturation and site of protease 
digestion. As a result, naturally occurring TSEs present different running patterns on western 
blots after digestion with PK (Casalone et al., 2004; Zanusso et al., 2004). In addition, 
different prion strains can co-exist within one individual (Polymenidou et al., 2005; Yull et 
al., 2006), suggesting a possible competition between different PrPC-recruiting PrPSc 
templates for prion conversion. Therefore, it is possible that a prion strain with a higher 
affinity for PrPC but less profound pathological consequences would decrease the 
pathogenesis caused by a co-existing strain with more important physiological consequences. 
However, the formal demonstration that the biological basis of prion strains is encoded within 
structural differences of PrPSc has not been possible yet, in part because of the difficulty of 
performing structural studies on infectious isolates. It has been suggested that the ratio of 
distinct glycoforms of PrP (un-, mono- and diglycosylated) (Collinge et al., 1996) may 
influence the structure of infectious PrP species, determining strain properties (Collinge, 
2005). However, more recent results deny this view (Piro et al., 2009). Finally, strain 
properties are also defined by host-encoded PrPC (Nonno et al., 2006). As a result, cell-based 
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assays can only replicate prion strains to which the cell clones have been selected for (Klohn 
et al., 2003; Solassol et al., 2003). This limitation, though, provides an opportunity to 
investigate the so far unidentified factors governing cell tropism and the phenomena of prion 
mutation and selective amplification of prion strains (Li et al., 2010). 
THE CELLULAR PRION PROTEIN 
The expression pattern of PrPC 
Expression of the cellular prion protein is highly conserved in mammals and has been 
identified in birds (Harris et al., 1993), in amphibian (Strumbo et al., 2001), in turtles 
(Simonic et al., 2000) and more recently in fish (Rivera-Milla et al., 2003). Although PrP-
deficient mice are generally believed to perform well despite the absence of PrP, an 
evolutionary pressure must exist to counterbalance the susceptibility of Prnp-expressing 
individuals to prion disease (Mead et al., 2003). It is therefore plausible that PrPC must have 
an important function. PrPC is highly expressed in the CNS and in several peripheral tissues 
including heart, skeletal muscle, kidney and lymphocytes (Dodelet and Cashman, 1998; Ford 
et al., 2002). However, ectopic PrPC expression can be triggered by inflammatory conditions 
in organs that normally express very low amounts of PrPC, thereby supporting prion 
replication competence (Heikenwalder et al., 2005). In the CNS PrPC is mainly expressed on 
neurons, and to a lower extent on other neural cell types including astrocytes and 
oligodendrocytes (Moser et al., 1995). 
The biosynthesis of PrPC 
Upon transcription, an unprocessed PrP polypeptide comprising 254 amino acids is directed 
towards the membrane of the endoplasmic reticulum (ER) by a 22 amino acids N-terminal 
hydrophobic signal sequence (in mice and hamsters) which is removed after ER translocation 
(Stahl et al., 1987).  A GPI-anchor replaces 23 amino acids at the C-terminus (Stahl et al., 
1987) and high mannose glycans are attached to the polypeptide at residues 180 and 196 and 
processed to complex glycans during transport through the Golgi apparatus (Bolton et al., 
1985). Mature PrPC molecules are then transported by secretory vesicles to the plasma 
membrane and anchored by the GPI-moiety at the outer cell surface. The deletion of both 
glycosylations causes intra-cellular accumulation of PrPSc (Cancellotti et al., 2005), although 
the presence of 1 out of the 2 glycosylations is sufficient for appropriate cellular trafficking of 
PrP. In cell culture, most PrPC undergoes endocytosis and degradation via the lysosome or 
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proteasome pathway (Caughey et al., 1989), however 10 to 30 % of PrPC is shed into the 
medium (Borchelt et al., 1990). 
The structure of PrPC 
Murine, bovine, canine, feline and human mature PrPC, as well as a prion protein recently 
characterized in other mammals (e.g.: tammar wallaby (Christen et al., 2009)) have a similar 
three-dimensional structure comprising a globular domain (residues 125 to 228) and a flexible 
N-terminal part of about 100 residues (residues 23 to 124 (Donne et al., 1997; Riek et al., 
1997; Viles et al., 2001)). The fold of the globular domain is defined by a two-stranded anti-
parallel sheet, three -helices, and a disulphide bond linking helices two and three (Riek et 
al., 1996b; Hornemann et al., 1997; Riek et al., 1997). The unstructured N-terminal part 
contains two defined and conserved regions: the first one is a segment of five repeats of an 
eight amino acids sequence and is called the octarepeat region. This region was suggested to 
be involved in copper binding and may be involved in prion pathogenesis since its expansion 
by insertional mutations provokes inherited prion disease (Brockes, 1999). The octarepeat 
region is flanked by two positively charged sequences named “charge clusters”, CC1 
(residues 23–27) and CC2 (residues 95–110). These domains are linked by a hydrophobic 
stretch of amino acids (residues 111–134), also termed hydrophobic core. This region is 
evolutionarily extremely well conserved although its potential function is so far unknown 
(Figure 3, adapted from: (Aguzzi et al., 2008)). 
 
 
 
Figure 3: The structure of the human PrPC. Adapted from: (Aguzzi et al., 2008). 
The mature human PrPC protein contains 208 amino acid residues. It features two positively charged amino acid 
clusters denoted CC1 and CC2 (blue boxes), an octapeptide repeat region (OR) (green boxes), a hydrophobic 
core (HC) (gray box), three α-helixes (H1-H3) (red boxes), one disulphide bond (S–S) between cysteine residues 
179 and 214, and two potential sites for N-linked glycosylation (red forks) at residues 181 and 197. A 
glycosylphosphatidylinositol anchor (GPI) (yellow box) is attached to the C-terminus of PrP. 
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The physiological function of PrPC 
The presence of PrP on the cell surface as a GPI-anchored extracellular molecule suggests a 
role in cell adhesion, intercellular interaction or as a signaling molecule. Mice devoid of PrPC 
were initially reported to have no phenotype (Büeler et al., 1992). Later reports, however, 
suggested mild alterations in hippocampal synaptic function (Collinge et al., 1994) as well as 
in circadian rhythm and sleep-pattern of PrP-deficient mice (Tobler et al., 1996). Furthermore, 
post-developmental ablation of PrPC was reported to lead to subtle alterations in hippocampal 
synaptic function, identical to what was seen in PrP-null mice, excluding that compensatory 
developmental effects are masking a stronger PrP-related phenotype (Mallucci et al., 2002). 
Unfortunately, most of these results could not be reproduced by other groups (Herms et al., 
1995; Lledo et al., 1996). PrPC was recently proposed to be important for the self-renewal of 
long-term repopulating haematopoietic stem cells (Zhang et al., 2006) and a positive regulator 
of neural precursor proliferation during developmental and adult neurogenesis (Steele et al., 
2006). More recently, chronic demyelinating polyneuropathy has been evidenced in PrPC-
deficient mice (Bremer et al., 2010), which suggests a role of PrP in myelin maintenance. The 
relatively low impact of the absence of PrPC on animal’s life and physiology blur the view of 
a direct function of PrP in any of the above-mentioned roles and confronts with the fact that 
PrPC is nevertheless evolutionarily conserved. 
ANTIPRION THERAPY 
Known antiprion compounds 
To date, no efficient treatments against protein aggregation diseases are available (Appleby 
and Lyketsos, 2011). The assumption that PrPSc plays a central role in prion disease has 
motivated approaches based on the identification of compounds that influence amyloid 
formation or clearance of PrPSc and PrPSc stability. Another important aspect of potential 
antiprion compounds is their bioavailability, as medicaments targeting the brain would need 
to be able to cross the blood-brain barrier (BBB). Inhibition of PrPSc conversion in cultured 
cells chronically infected with prions (Korth et al., 2001) or in animal models (Pocchiari et al., 
1987) have been reported for molecules that are known to cross the BBB such as 
amphotericin B (Pocchiari et al., 1987), quinacrine and chloropromazine (Korth et al., 2001). 
However, clinical trials in humans revealed no significant improvements of the course of 
chronic disease (Benito-Leon, 2004; Martinez-Lage et al., 2005; Collinge et al., 2009). 
Amyloid deposition is thought to progress within one organism by the propagation of 
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infectious seeds (Aguzzi and Calella, 2009) and prion fibrils may propagate through breaking 
and elongation of infectious seeds into new fibrils (Wang et al., 2011). Thus, fibril frangibility 
may be a critical parameter of their infectivity (Caughey and Lansbury, 2003; Knowles et al., 
2009). Compounds that stabilize aggregated prion particles may decrease prion infectivity and 
therefore could be valuable tools for the treatment of prion diseases or prophylactic measures. 
Congo red (CR) (Ingrosso et al., 1995) and the fluorescent antracycline iododoxorubicin 
(Tagliavini et al., 1997) were reported to prolong incubation time in rodents upon co-
inoculation with prions. Although many prion disinfectants degrade or disaggregate PrPSc, CR 
was found to interfere with one or more steps in the conversion of PrP by stabilizing PrP 
aggregates (Caspi et al., 1998). In addition, several polyanions can interfere with prion 
replication. The structural requirements for anti-scrapie activity of sulphated polyanions in 
chronically infected cells were investigated in detail (Ouidja et al., 2007). The most promising 
compound, pentosan polysulfate (PPS) (Tsuboi et al., 2009; Terada et al., 2010) is currently 
undergoing clinical trials, although its hydrophobic nature hinders CNS penetration 
(MacGregor et al., 1985). However, these compounds are believed to interfere with the 
interaction of endogenous glycosaminoglycans with PrPC and/or PrPSc rather than acting 
directly at the level of PrPSc aggregates. Finally, complex polyamines have been shown to 
disaggregate PrP but also suffer poor bioavailability (Supattapone et al., 2009). The discovery 
of new classes of compounds with better bioavailability that directly influence amyloid 
formation is therefore of high interest. 
Conjugated polythiophenes 
Conducting polymers (CPs) are a particular group of chemically engineered polymers with 
electronic and ionic conductivity. CPs were initially developed for broad applications in the 
field of electronics, however the chemical synthesis of numerous derivatives has extended 
their potential use in various fields such as the food industry but also the development of 
biomedical devices, neural prosthetics, antioxidants and biosensors (Ravichandran et al., 
2010). Luminescent conjugated polythiophenes (LCPs) (Figure 4) are a subgroup of CPs that 
have good electrical conductivity and optical properties and have recently been proven as 
novel tools to investigate amyloids (Herland et al., 2005; Nilsson et al., 2005; Nilsson et al., 
2006; Nilsson et al., 2010). Upon binding to the amyloid scaffold the LCPs are able to adopt 
distinct conformations with characteristic spectral properties that have recently been used for 
prion strain discrimination (Sigurdson et al., 2007) (Figure 5, adapted from (Sigurdson et al., 
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2007)) and the characterization of amlyoid aggregates associated with other protein 
aggregation diseases (Nilsson et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of LCPs as novel dyes for aggregated proteins associated with several 
neurodegenerative disorders illustrate their very strong affinity and specificity for amyloid 
aggregates. This suggests a potential as anti-prion compounds, because molecules that are 
able to bind PrP aggregates may stabilize them, thereby preventing the release of prion 
infectious seeds. In fact, this would not be the first time that a molecule initially used as a dye 
for amyloid structures would present antiprion activity, and indeed CR has been shown to 
bind to and stabilize PrPSc (Caspi et al., 1998). Recently, a new generation of these molecular 
probes called luminescent conjugated oligomers (Aslund et al., 2007; Aslund et al., 2009) 
(Figure 4, pHTAA and pFTAA) has been developed for broadening their use in protein 
aggregation research. As these molecules cross the BBB they enable further development of 
visualization of protein aggregates in vivo as well as prophylactic and therapeutic trials in 
laboratory animals. In this thesis I refer to all luminescent polythiophenes that I used as LCPs. 
 
 
 
Figure 4: Molecular structures of LCPs. 
Luminescent conjugated polythiophenes (LCPs). pHTAA and pFTAA are homodispersed 
preparations of chemically defined molecules with molecular weights of 897 and 704.7 Da, 
respectively. All other compounds are polydisperse preparations with average molecular weights 
ranging from 3000 to 11000 Da and number of monomers of n=11-20 or 1500 Da with n=3 for 
tPOWT. PTAA and its derivatives pHTAA and pFTAA are anionic compounds. POMT, PTMI and 
PBAT are cationic and POMT and tPOMT are zwitterionic. 
A B 
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Figure 5: PTAA and thioflavin T staining of PrP deposits in prion-infected brain 
cryosections. Adapted from (Sigurdson et al., 2007) 
 
(A) Images showing PTAA and thioflavin T bound to PrP aggregates from CWDtga20, NStga20 and 
some BSEWT. To show the localization and the selective staining of the PrP aggregates, low and 
high magnifications of the boxed regions are shown for CWDtga20 and NStga20. 
(B) Spectra of PTAA bound to CWDtga20 (black), NStga20 (purple) and BSEWT (blue) deposits. –, 
Emax; *, E532 nm; +, E639 nm. Background signal, black line. Scale bars, 500 µm (A; PTAA, 
top), 50 µm (A; PTAA, middle, and thioflavin T). 
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The prion organotypic slice culture assay 
The prion organotypic slice culture assay (POSCA) (Falsig and Aguzzi, 2008; Falsig et al., 
2008) is a novel, flexible and robust experimental system to study prion infection in cultured 
organotypic cerebellar slices (COCS), which allows for determination of prion infectivity and 
for studying prion replication ex vivo in a complex cellular environment. The POSCA is a 
versatile research platform that enables various manipulations of the tissue such as depletion 
or addition of specific cell types or treatment with various compounds. COCS are 
morphologically relevant as they retain the architecture of the originating brain tissue (e.g.: 
intercellular connections) while harboring disease-induced changes such as accumulation of 
aggregated PrP and prion-induced neuronal loss, allowing for the study of the role of different 
cell types in prion replication and pathogenesis. The operating characteristics of the POSCA 
are close to the most commonly used prion titration assays: the Scrapie cell end point assay 
(SCEPA) (Klohn et al., 2003; Falsig and Aguzzi, 2008; Falsig et al., 2008) and the mouse 
endpoint bioassay (Fischer et al., 1996). Furthermore, ex vivo organotypic brain slice cultures 
can be prepared from mice of any genotype and allow for depletion of specific cell types. This 
makes it a versatile tool to study the phenomena of strain adaptation and strain propagation 
(Weissmann, 2004). Multiple passages of a prion strain can be generated in a well-controlled 
manner in a relative short period of time. In addition the tissue can easily be manipulated and 
drugs and other compounds can be administrated via the culture medium. 
PRION STRAIN TYPING USING LCPs  
Prion strain adaptation 
Prion strain adaptation is usually observed when an infectious prion isolate is transmitted 
across different species (Beringue et al., 2008). As an example, when prions obtained from a 
Scrapie-sick sheep are inoculated (in the form of a brain homogenate) to a cohort of mice, the 
incubation period is typically long. Successive passages in mice can be performed by 
transmitting brain homogenates into further generations of mice. As a result, the incubation 
time shortens and the attack rate and severity of the disease stabilizes, yielding what is 
referred as a “mouse-adapted prion strain”. Recently, LCPs have been used to reveal discrete 
structural changes of PrP aggregates upon strain adaptation of cervid prions into mice 
(Sigurdson et al., 2007) (Figure 6, adapted from (Sigurdson et al., 2007)). 
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Figure 6: Spectral data of mouse PrP deposits stained with PTAA. Adapted from: (Sigurdson et 
al., 2007) 
(A,B) Correlation diagram of the ratios of emitted intensities, R532/639 and R532/Emax, of the 
intensity of the emitted light from PTAA bound to PrP plaques in individual NStga20, CWDtga20, 
NSWT and BSEWT. The image in (B) is an expansion of the marked region in (A), and depicts four 
passages of CWD in tga20 mice.  
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AIM OF THE THESIS 
To date no treatment is available for TSEs, which remain invariably lethal diseases. The 
strong interaction of LCPs with the amyloid scaffold was the rationale for the main focus of 
my thesis: investigate and characterize the antiprion effects of LCP treatment on COCS and 
unravel the underlying mechanisms. The first milestone was to establish that LCPs do have an 
effect on prion accumulation in prion-replicating COCS by using different methods as a read-
out. I used quantitative methods such as SCEPA, MPA and ELISA. I also wanted to directly 
visualize prion aggregates and/or PK-resistant prions by using non- or semi-quantitative 
methods such as histoblot and Western blot. Finally, another important aspect was to 
appreciate if the effects of LCPs on prion replication would reduce prion-induced 
neurotoxicity by using a semi-quantitative method recently developed by my colleague Dr. 
Jeppe Falsig (neuronal cell death measurement in COCS by quantification of NeuN+ area in a 
fluorescent microscope). This technique also enabled investigation of the potential toxicity of 
LCPs to brain cells. The second milestone was to unravel the mechanisms underlying the anti-
prion effect of the selected LCP candidate PTAA. I used semi-quantitative methods such as 
Western blot and conformation-stability assay to investigate proteolysis of PrP in the presence 
of LCPs. I used quantitative methods such as bioassays in mouse or in cells. Finally I also 
investigated fibrilization of recombinant PrP (recPrP) in the presence of LCPs in a 
quantitative manner to elucidate the potential of an LCP to block PrP conversion. 
The second part of my thesis focuses on prion strain discrimination in COCS. The goal was to 
partly reproduce the work of Sigurdson et al. in COCS in order to develop a straightforward 
method to study phenomena such as prion strain adaptation and prion strain competition in a 
fast manner. 
In the third part of my thesis I describe collaborative work that I performed during my first 
year of PhD under the supervision of PD Dr. Mathias Heikenwälder. The goal of this work is 
to investigate peripheral prion pathogenesis of human prions by using a model of transgenic 
mice lacking B and T cells (Cγ-/-RAG2-/-) which immune system was reconstituted with 
human embryonic stem cells. 
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RESULTS 
PART I: LCPs INHIBIT PRION PROPAGATION BY STABILIZING 
PRION AGGREGATES 
In the first part of my thesis I describe the antiprion potential of LCPs in prion-infected brain 
slices and the putative mechanism by which LCPs interfere with prion replication upon 
reacting with aggregated PrP. 
Chronically prion-infected, LCP-treated COCS have variable signal for 
PK-resistant material on Western blot 
I used the cationic and anionic LCPs PBAT and PTAA respectively for preliminary 
experiments to determine whether LCPs inhibit prion replication in COCS. However, for the 
further characterization of LCP treatment of COCS I focused on PTAA as this molecule was 
available in suitable amounts. COCS were prepared from 11 days-old PrPC-overexpressing 
tga20 pups, infected with RML6 and harvested after 35 or 42 days according to Falsig et al. 
(Falsig and Aguzzi, 2008; Falsig et al., 2008) with treatment started at 21 DIV (LCPs were 
added to the culture medium three times per week) (Figure 7). 
 
 
 
 
 
For clarity I refer to brain homogenate obtained from COCS as COCSBH. The presence of 
PrPSc in COCSBH was analysed by controlling for PK-resistant material on a Western blot 
(WB) (Figures 8A, lane 4). After PK digestion, prion-infected COCSBH yielded PK-resistant 
material migrating as three bands with molecular sizes between 18-27 kDa. In some cases, as 
in normal BH, additional bands can be observed between 37 and 75 kDa and are referred as 
“higher order aggregates”, although their appearance on the nitrocellulose membrane is 
Figure 7: Experimental setup for treatment of prion-infected slice cultures with 
polythiophenes. 
Red arrows: addition of LCPs to the culture medium. Grey arrows: tissue can be analyzed at 
various time points. 
                    RESULTS
 _____________________________________________________________________ 
27 
 
generally of a weaker intensity. My first attempt to treat chronically-infected slices with 
PBAT and PTAA yielded a surprising result: treated cultures had increased PK-resistant 
material on WB (Figure 8A, lane 6 and Figure 9A, lanes 6-9). In addition, I observed an 
increased amount of higher-order aggregates. Immunoblots of non-digested COCSBH show 
that treatment with PBAT does not affect PrPC levels (Figure 8B, lane 8) in accordance with 
the experiment conducted in N2a-PK1 cells by C. Julius and K.P.R. Nilsson (see discussion). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9, in which all cultures were harvested at 35 DPI, shows the dose-dependent effect of 
PTAA. Surprisingly, high-dose PTAA treatment (60 µg/ml) (Figure 9, lane 5) lowered the 
signal for PK-resistant material. 
 
 
 
 
Figure 8: PBAT-treated slice culture homogenates have increased signal for PK-resistant 
material on Western blot. 
(A) Immunoblot of PK-digested slice culture homogenates harvested after 21 or 35 DIV, untreated 
(PBAT -) or treated with 10 µg/ml PBAT (PBAT +). 
(B) Immunoblot of samples shown in (A), undigested. On lane 1 in (A) and (B) 2 µg undigested 
RML6 BH was loaded. On lane 2 in (A) and (B) 20 µg PK-digested RML6 BH was loaded. In all 
other lanes 20 µg total protein from slice culture homogenates was loaded. Mock: slice culture 
homogenates from tga20 slices exposed to non-infectious BH from a CD1 mouse. This experiment 
was repeated twice. The anti-PrP antibody POM1 was used for the detection. Molecular sizes are 
indicated in kDa. 
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As the correlation of PK-resistant material with other markers for prion load (e.g. prion 
infectivity, presence of PK-sensitive prion aggregates) is not clear, I sought to determine the 
prion content of PTAA-treated slices with other methods. For this purpose, I repeated the 
titration experiment shown in Figure 9 in biological triplicates, including prion-infected 
cultures treated with pentosan polysulfate (PPS) as a control for reduction of prion 
accumulation. I chose to use PPS because its anti-prion effect is widely recognized and 
because my colleague Dr Falsig used it to develop the POSCA. I extended the culturing 
period to a total of six weeks and included prion-infected cultures that were harvested at 21 
DPI. Immunoblots from one series of these replicas is shown in Figure 10. This experiment 
reproduces well the results shown in Figure 9. Treatment with PPS resulted in a signal for PK-
resistant material that lies between that of untreated slices harvested at 21 or 42 DPI. 
Immunoblots from the other two series of biological replicas revealed identical patterns of 
PK-resistant material (not shown). 
 
 
 
 
Figure 9: PTAA-treated COCSBH have modified signal for PK-resistant material on 
immunoblot. 
(A) Immunoblot of a titration of PTAA for treatment of prion-replicating slice cultures. COCSBH 
harvested after 35 DIV, untreated (PTAA -) or treated with various dilutions of PTAA were 
digested with PK. 2 µg undigested RML6 BH was loaded in lane 1 and 20 µg PK-digested RML6 
BH was loaded in lane 2. In all other lanes 20 µg total protein from COCSBH was loaded. 
(B) Immunoblot of samples shown in (A), undigested. The anti-PrP antibody POM1 was used for 
the detection. Molecular sizes are indicated in kDa. 
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Chronically prion-infected, PTAA-treated COCS have lower prion 
infectivity titre 
In collaboration with Carlo Suter, I used the SCEPA to measure prion infectivity titres of 
biological triplicates (Figure 11). The average infectious titre of prion-infected, untreated 
COCSBH ranges from 5.66 for tissue harvested at 21 DIV to 7.38 logID50 for tissue harvested 
at 42 DIV. Treatment with PPS or with 6 to 60 µg/ml PTAA significantly decreased prion 
infectivity (respectively p = 0.012, p = 0.001 and p < 0.001, Table 1). Notably, treatment with 
60 µg/ml PTAA brought infectivity titres of COCSBH below those of samples harvested at 21 
DIV. COCSBH from cultures treated with 0.01 µg/ml PTAA were excluded from the 
statistical analysis for mathematical reasons. 
 
 
Figure 10: Immunoblot of a series of biological triplicates of prion-replicating COCS treated 
with a titration of PTAA. 
20 µg total protein from COCSBH harvested after 21 or 42 DIV, untreated (PTAA -) or treated 
with PPS (PPS: 0.3 µg/ml) or with various dilutions of PTAA were digested with PK. The anti-PrP 
antibody POM1 was used for the detection. Molecular sizes are indicated in kDa. 
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Chronically prion-infected, PTAA-treated COCS have lower reactivity 
with prion-specific binding peptoids 
To further investigate prion accumulation in our cultures, I quantitatively determined prion 
load in COCSBH by using the misfolded protein assay (MPA) (Lau et al., 2007; Kranich et 
al., 2010; Polymenidou et al., 2011) (Figure 12). The MPA is a novel assay that enables 
sensitive and quantitative detection of prion aggregates without the use of PK. Paramagnetic 
beads coated with prion-specific binding peptoids are used to specifically capture prion 
aggregates, whereas monomeric PrP is not captured. After elution of PrP from the beads it is 
detected by a standard ELISA using the PrP-specific antibody POM19. Treatment of cultures 
Figure 11: PTAA treatment decreases prion infectivity of COCS in a dose-dependent 
manner. 
Prion infectivity titres of biological triplicates of COCSBH from COCS untreated or treated with 
PPS or PTAA were determined in the SCEPA. Infectivity titres of uninfected cultures harvested 
after 21 or 42 DIV are shown for comparison. Each diamond represents the infectivity titre of a 
COCSBH determined by serial tenfold dilution from 10-4 to   10-8 on a 96-well plate. Error bars 
represent the mean ± SEM of biological triplicates. P-values represent ID50 difference to control 
and are shown in Table 1. ***: p < 0.001. **: p < 0.01. *: p < 0.05. Detection limit: Theoretical 
titer based on the observation of false positives at concentrations between 10-2 and 10-3 of non-
infectious inoculum (CD1). n.s.: non significant. n/a: these results were not included into the 
statistical analysis. Part of the SCEPA analysis was performed by Carlo Suter. 
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with PPS as well as with PTAA concentrations ranging from 0.1 to 60 µg/ml significantly 
decreased the signal in the MPA. Thus, this analysis further indicates that treatment with 
PTAA brings prion content of COCS below that of untreated tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To exclude the possibility that accumulation of PTAA in COCS could interfere with my 
methods I quantified fluorescence from COCSBH. I generated a standard curve by spiking 
PTAA into CD1 or RML6 BH or water and compared fluorescence from PTAA in COCS BH. 
I found that treatment of cultures with 60 µg/ml PTAA for three weeks resulted in a 
fluorescent signal in COCSBH that corresponds to less than 15 ng/ml PTAA spiked in brain 
homogenate (Figure 13). As the treatment of a brain homogenate with 1 µg/ml PTAA had no 
effect on the signal for RML6 prions in the MPA (see Figure 30), nor on the release of prion 
infectivity measured in the SCEPA (see Figure 26A) (Margalith et al., 2012), I conclude that 
PTAA treatment of COCS results in a concentration of PTAA within COCSBH that does not 
affect my methods. 
Figure 12: PTAA treatment decreases reactivity with prion-specific binding peptoids of 
COCSBH in a dose-dependent manner. 
MPA of COCSBH shown in Figure 10. Each dot represents the average value of technical 
triplicates for one COCSBH. Error bars represent the mean ± SEM of biological triplicates. All data 
were corrected for the negative control (CD1 BH) and represented as relative light units (RLU). P-
values represent difference to control and are shown in Table 2. ***: p < 0.001. n.s.: not significant. 
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Chronically prion-infected, PTAA-treated COCS have less PK-resistant 
material by ELISA 
In order to investigate the discrepancy between the results of immunoblots and SCEPA/MPA, 
I sought to measure PK-resistant material of COCSBH using an ELISA for PrP. In 
collaboration with Boris Ballmer I measured PrP epitopes to POM1 in undigested as well as 
PK-digested COCSBH from the biological triplicates shown in Figures 11 to 12. COCSBH 
from PTAA-treated cultures had less PK-resistant material than COCSBH from untreated 
cultures (Figure 14A). No signal for PK-resistant PrP could be detected in COCSBH from 
cultures treated with 60 µg/ml PTAA. PrPC levels remained relatively constant (no 
statistically significant difference) apart in COCSBH from infected tissue treated with 60 
µg/ml PTAA where a significant decrease could be observed (Figure 14B) (Table 4). 
 
Figure 13: PTAA is present in negligible amounts in COCSBH from PTAA-treated cultures. 
Fluorescence of PTAA or vehicle only (water, grey dotted line) spiked in (A) CD1 BH, (B) RML6 
BH, or present in (C) COCSBH from PTAA-treated, non-infected cultures (CD1) and (D) 
COCSBH from PTAA-treated, RML6-infected cultures (RML). (C, D) Buffer: PBS. Empty: empty 
well of a 96-well plate. 
A B 
C D 
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Figure 14: PTAA treatment of COCS decrease PK-resistant material measured by ELISA. 
(A) PrPSc levels of COCSBH shown in Figures 9-11, PK-digested. Each dot represents the average 
value of technical duplicates for one COCSBH. Error bars represent the mean ± SEM of biological 
triplicates. All data were normalized to protein concentration of the corresponding sample. P-values 
represent difference to control and are shown in Table 3. 
(B) PrPC levels of COCSBH shown in (A). P-values represent difference to control and are shown 
in Table 4. The technical part of the ELISA analysis was performed by Boris Ballmer. 
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Correlation between MPA, SCEPA and ELISA 
In order to validate my methods in the frame of the use of PTAA as an anti-prion compound 
as well as to convince myself of the anti-prion effect of PTAA I sought to better picture the 
correlation between data harvested by SCEPA, MPA and ELISA. Figure 15 displays 
correlation diagrams between for data shown in figures 11 (SCEPA), 12 (MPA) and 14 
(ELISA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Correlation diagrams 
for data measured by SCEPA, 
MPA and ELISA. 
(A) Correlation diagram to show the 
relationship between SCEPA and 
MPA data presented in Figures 11 
and 12. (B) Correlation diagram to 
show the relationship between 
SCEPA and ELISA data presented 
in Figures 11 and 14. (C) 
Correlation diagram to show the 
relationship between MPA and 
ELISA data presented in Figures 12 
and 14. 
 A 
B 
C 
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Chronically prion-infected, PTAA-treated COCS have fewer foci of 
deposition of PK-resistant PrP on histoblots 
In order to visualize the areas of deposition of PK-resistant material in COCS I prepared 
tissue for histoblots. Briefly, tissue was applied onto nitrocellulose membrane which allows 
for transfer of proteins to the membrane. PK-digestion was performed and PrP epitopes were 
revealed using an HRP-conjugated anti-PrP antibody (POM1-HRP). Non-infected COCS 
digested with PK were devoid of PrP epitopes, whereas PrPC was present in non-infected, 
undigested COCS (Figure 16A). Discrete foci of deposition of PK-resistant material could be 
seen in RML-infected, PK-digested COCS at 21 DPI and were more abundant at 42 DPI 
(Figure 16B). Treatment with PPS (300 ng/ml) or with PTAA (0.1 to 100 µg/ml) decreased 
foci of deposition of PK-resistant material to a level that was comparable to the situation at 21 
DPI. Petra Schwartz performed the histoblot analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 16: PTAA-treated COCS have fewer foci of deposition of PK-resistant material. 
(A) Histoblots of non-infected COCS (negative controls). 
(B) Histoblots of RML-infected COCS treated with PPS or PTAA. Histoblots were performed by 
Petra Schwartz. 
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PTAA treatment of chronically prion-infected COCS in a time-course 
manner 
Next I wanted to investigate the effect of PTAA treatment in a time-course manner.                       
I prepared and prion-infected slice cultures in biological duplicates and harvested the tissue at 
7, 19, 21, 28, 35 and 42 DIV. In parallel, I performed PTAA treatment (fixed concentration: 
10 µg/ml) of cultures by starting the administration of PTAA from day 7, 19, 21, 28 or 35.      
All cultures were harvested at 42 DPI. Treatment with PTAA started from either time-point 
resulted in an absence of signal in the MPA (Figure 17A). As PrP aggregates can be detected 
by the MPA at 7 DPI already in prion-infected COCS, the impossibility to detect them in 
prion-infected, PTAA-treated COCS may be due to a modification of PrP aggregates by the 
presence of PTAA. 
I then measured PrP epitopes of the samples shown in Figure 17A by ELISA (Figure 17B and 
C). For this part (Figure 17B and C), additional cultures were prepared later on to obtain a 
third replica for each time point as well as additional time points (45, 49 and 56 DIV).               
PK-resistant PrP in untreated COCS could be detected at 21 DIV and increased during the 
course of the experiment (Figure 17B). Treatment with 10 µg/ml PTAA from day 28 kept the 
level of PK-resistant PrP at the level of the corresponding time point in untreated tissue, 
whereas treatment started from day 35 resulted in a decrease of PK-resistant PrP.                   
Thus, PTAA-treated cultures seem to contain equal or lower levels of PK-resistant material 
than untreated cultures. It cannot be excluded, however, that PTAA treatment induces a 
modification of PrP aggregates that interferes with my method. PrPC levels of COCS are 
shown in Figure 17C. PTAA treatment started at either time-point decreased PrPC levels about 
two fold. 
 
 
 
 
 
 
 
 
 
 
Figure 17 (next page): PTAA inhibits prion accumulation in RML6-infected slice cultures 
from different time points 
(A) MPA of homogenates from RML6 infected slices harvested at days 7, 19, 21, 28, 35 and 42 
DIV. PTAA was administered at a concentration of 10 µg ml-1 at the time of medium change 
freshly into the medium from days 7, 19, 21, 28 or 35 DIV. Slice cultures were harvested at 42 DIV 
and analyzed for PrP aggregates. Each dot represents the average value of technical triplicates for 
one slice culture homogenate. Error bars represent the mean ± SEM of biological duplicates. All 
data were corrected for non-infectious brain homogenates obtained from CD1 mice as negative 
control (mock) and represented as the ratio between relative light units (RLU) and protein 
concentration for each sample. P-values are shown in Table 5. (B) Sandwich ELISA of the same 
homogenates as in (A) analysed for PrPSc. The data are represented as biological triplicates. The 
signal for the negative control (mock) is shown as single replica. (C) Sandwich ELISA of the same 
homogenates as in (A) analysed for PrPC. The ELISA was developed by chemiluminescence. The 
detection limit of 600 pg ml-1 (dashed line) was determined as the mean background levels plus 
three times SD. 
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PTAA treatment rescues prion-induced neurodegeneration of chronically 
prion-infected COCS 
Next, I asked if the inhibitory effect of PTAA on prion accumulation in chronically prion-
infected COCS would prevent neurodegeneration. Prion-induced neurodegeneration in brain 
slices is generally appreciated as a 40-70% loss of cerebellar granule neurons (CGNs) at 42 
DPI, which can be quantified upon staining with the antibody NeuN. I recorded the NeuN-
positive area in 10 to 30 slices per condition (Figure 18) and observed a marked loss of CGNs 
in prion-infected COCS as compared to non-infected tissue (p < 0.001, n = 30). Treatment 
with PPS or PTAA led to a significant rescue of CGNs in prion-infected COCS (p < 0.001, n 
= 10), showing that inhibition of prion replications by PPS or PTAA blocks prion toxicity. In 
contrast, there was no statistically significant difference between uninfected cultures left 
untreated or treated with PPS or PTAA (6 and 60 µg/ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Neurodegeneration is prevented in PTAA-treated slice cultures. 
Viability of slice cultures determined by quantification of NeuN+ area in 11 to 30 slices per 
condition. Empty boxes: COCS exposed to non-infectious BH (CD1). Boxes with pattern: prion-
infected COCS. The boundaries of the boxes represent the 25th to 75th percentiles. Whiskers 
represent the minimal and maximal values. The line in the middle of the box represents the median. 
Each data point represents one measurement taken on an entire slice. Data was collected from 11 to 
30 slices. ***: p < 0.001. Statistical analysis is provided in Table 6.  
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LCPs increase the resistance to proteolysis of RML6 prions 
In this part of my work I sought to characterize the effects of LCPs on a prion-containing BH. 
A comprehensive library of different LCPs with different charged side-chains and/or different 
length of their thiophene backbone (Figure 4) was used in this study, including the anionic 
PTAA (Nilsson et al., 2005; Nilsson et al., 2006; Aslund et al., 2007; Nilsson et al., 2007) and 
its derivatives pHTAA and pFTAA (Aslund et al., 2009); the cationic POMT (Nilsson et al., 
2006; Aslund et al., 2007; Nilsson et al., 2007), PTMI (Ho et al., 2002), and PBAT 
(unpublished); and the zwitterionic POWT (Nilsson and Inganas, 2003; Nilsson et al., 2003; 
Aslund et al., 2007),  and tPOWT (Aslund et al., 2007). As PK-resistant PrPSc is a surrogate 
marker for prion diseases that can be observed upon proteolysis of a prion-containing BH, I 
first tested whether LCPs affect the proteolysis of RML6 prions. Figure 19 shows that 
incubation of 1% RML6 BH with increasing concentrations of the LCPs ranging from 1 to 
900 µg/ml increased the level of PK-resistant PrPSc on a Western blot in a dose-dependent 
manner and caused the occurrence of higher-order aggregates. 
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Figure 19: LCPs increase the resistance of PrPSc to PK digestion and induce the formation of 
higher order aggregates. 
Immunoblots of PK-digested RML6 samples after treatment with increasing concentrations of the 
different LCPs. On lane 1 in the blots of the pHTAA and pFTAA titrations, 2 µg undigested RML6 
BH was loaded. On all other lanes 20 µg PK-digested uninfected (mock) or RML6-infected BH 
was loaded. This experiment was repeated four times with PTAA, and twice with the other LCPs. 
The anti-PrP antibody POM1 was used for the detection. Molecular sizes are indicated in kDa. 
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Next, I wanted to exclude that the addition of PTAA to already PK-digested RML6 prions 
affects the level of PrPSc. Figure 20A shows that the addition of PTAA to readily PK-digested 
RML prions does not change the signal for PrPSc. Therefore, the increase of the signal for 
PrPSc is only obtained by proteolysis of RML prions after they had interacted with PTAA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If PTAA or POMT were used at the highest concentrations of 50 and 100 µg/ml (Fig. 19, 
lanes 2 and 3 of upper blots), a decrease of signal was observed. In the case of POMT this was 
due to the presence of the LCPs on the nitrocellulose membrane which causes a reduction in 
the immunoreactivity of the anti-PrP antibody POM1. Indeed, 500 µg/ml POMT completely 
blocked immunoreactivity of POM1 (Figure 20B, lane 3). Protein transfer, however, occurred 
normally (Figure 21). The decrease of signal in PTAA-treated PrPSc with the highest doses of 
Figure 20: PTAA does not affect PK-digested prions. 
Proteolysis of RML before the addition of LCPs. All samples were digested with PK before 
addition of water or LCP. 
(A) Lane 1: 2 µg protein from CD1 BH, undigested. Lane 2: marker. Lane 3: 10 µg CD1 BH, 
digested. Lane 4: 10 µg RML6 BH digested before addition of water. Lanes 5-7: 10 µg RML6 BH 
digested before addition of PTAA, respectively: 10, 1 and 0.1 µg/ml. 
(B) Lanes 1-4 contain 20 µg PK-digested protein from RML6 BH mixed either with water (lanes 1 
and 4) or PTAA 5000 µg/ml (lane 2) or POMT 500 µg/ml (lane 3). Lane 5 contains 20 µg CD1 
BH. 
(C) Nitrocellulose membrane of blot shown in (B). 
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50 and 100 µg/ml cannot be attributed to a similar artefact as with POMT because fewer or no 
PTAA binds to the membrane (Figure 20C, lane 2) (PTAA is anionic, POMT is cationic). 
 
 
 
 
 
 
 
 
 
 
 
Incubation of RML6 with PBAT and POWT affected only weakly the relative signal for PrPSc 
but still caused the formation of higher order aggregates. Longer exposures of the blots 
revealed that the higher order aggregates are present for all LCPs, with the exception of 
tPOWT (Figure 22), which was also the only compound that did not affect the intensity of the 
signal for PrPSc (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: PTAA and POMT do not 
affect protein transfer. 
Ponceau red staining of a 
nitrocellulose membrane with 2 or 20 
µg total protein from CD1 BH, PK-
digested (+) or undigested (-), in the 
absence (+H2O) or presence of LCPs. 
Figure 22: Longer exposures of selected immunoblots from Figure 19 to evidence the 
appearance of higher-order aggregates in the samples treated with PTMI, PBAT and POWT 
and their absence in the samples treated with tPOWT. 
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I also performed, in collaboration with Carlo Suter, a PK digestion with a 40-fold higher 
concentration of PK on PTAA-treated RML6 and doubled the incubation time for the 
proteolysis to investigate the efficiency of PTAA on the protection of PrPSc to protolysis. The 
signal for untreated PrPSc was completely abolished under these conditions, PrPSc in PTAA-
treated samples remained detectable even under these harsh conditions (Figure 23), indicating 
that the LCPs strongly protect the PK-resistant core of PrPSc against proteolysis. 
 
 
 
 
 
 
 
 
 
 
The finding that the LCPs render PrPSc more resistant against proteolysis was rather 
unexpected, because therapeutic compounds usually operate in the way that they increase the 
sensitivity of PrPSc to PK digestion. I performed therefore several control experiments with 
PTAA to exclude that the presence of the LCPs affected the assay. I digested CD1 BH in the 
absence and presence of PTAA with PK to eliminate that the LCPs interfere with the function 
of the PK enzyme (Figure 24) and observed no noticeable difference in the efficiency of 
proteolysis neither for the PTAA-treated nor untreated PrPC.  
 
 
 
 
 
 
 
 
Figure 23: PTAA increases the resistance of PrPSc to PK 
digestion. 
Immunoblot of PK-digested RML samples incubated with 
water (lane 1) or with PTAA (lanes 2-4). Each sample is a 45 
µg protein aliquot. Proteolysis of all samples was performed 
with 2 mg/ml PK for 60 min. The anti-PrP antibody POM1 was 
used for the detection. Molecular sizes are indicated in kDa. 
This experiment was performed by Carlo Suter. 
Figure 24: PTAA does not affect the digestion of PrPC by PK. 
Proteolysis of PrPC (A) in the absence and (B) presence of PTAA. Lane 1 of each blot was loaded 
with 2 µg undigested protein (CD1 BH). Lanes 2-9 were loaded with 20 µg protein (CD1 BH) that 
was digested with limiting concentrations of PK. 
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Exposure of RML6 prions with LCPs reduces infectivity titre 
In order to evaluate the anti-prion potential of the LCPs on RML6 prions I used the SCEPA to 
perform a screening of the different LCPs to identify those with the strongest effects on a 
reduction of the infectivity titer. Figure 25 shows that all LCPs apart from tPOWT (data not 
shown) significantly reduced the infectivity titre of RML6 prions when used at a 
concentration of 300 µg/ml. pFTAA was found to be the most efficient compound (Table 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I chose to compare PTAA and its monodisperse derivative pFTAA and studied their effects 
on the infectivity of RML6 prions in a dose-dependent manner using concentrations ranging 
between 100-5000 µg/ml for PTAA (Figure 26A) and 75-900 µg/ml for pFTAA (Figure 26B). 
PTAA reduced the infectious titre of RML6 by 3 logs ID50/g when used at a concentration of 
900 µg/ml and completely abolished prion infectivity when RML6 was treated with a 
concentration of 5000 µg/ml PTAA. The effect of pFTAA on prion infectivity appeared 
similar to the effect of PTAA given the variability of the SCEPA (+/- 1 logID50/g) (Table 8). 
 
Figure 25: LCPs reduce prion 
infectivity in the SCEPA 
Comparison of the infectivity titres of 
RML6 after treatment with different 
LCPs using a concentration of 300 
µg/ml. Non-infected (CD1) and RML6-
infected BH were incubated with the 
LCPs and infectivity was determined on 
17’000 cells in the SCEPA. Each data 
point represents one sample determined 
by serial tenfold dilution steps from 10-4 
to 10-8 on a 96-well plate. Data are 
shown as mean ± SEM. The ID50 
represents the number of magnitudes a 
prion-containing sample has to be 
diluted in order to decrease its infectious 
titre by 50%, read as a 50% decrease in 
positive wells on a 96-well plate. P-
values represent statistical difference 
between LCP-treated and untreated RML 
BH and were calculated with a Mantel-
Haenszel Chi-square test with 
Bonferroni-Holm correction (Table 7). 
Detection limit: Theoretical titre based 
on the observation of false positives at 
concentrations between 10-2 and 10-3 of 
non-infectious inoculum. Part of this 
analysis was performed by Carlo Suter. 
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Next, I wanted to exclude that the ability of neuroblastoma cells to become infected with 
prions was affected by the presence of the LCPs themselves. In a first approach (described in 
Figure 27A) I added a 10-fold excess of RML6 to untreated or PTAA-treated RML6 samples 
prior to infection of the cells in order to control that the concentration of PTAA present in the 
infected medium was not affecting the susceptibility of the cells to prions. I observed that the 
infectivity titres did not significantly differ (Tables 9 and 10), showing that 500 µg/ml PTAA 
did neither affect the ability of the cells to become infected nor the read-out of the SCEPA. In 
a second approach (described in Figure 27B) I tested whether the pre-incubation of N2a PK1 
cells with PTAA added in the culture medium before infection reduces the susceptibility of 
the cells to prion infection. For this experiment, I used a PTAA concentration of 10 µg/ml 
Figure 26: LCPs reduce prion infectivity in the SCEPA 
(A) Concentration-dependent titration of PTAA. 
(B) Concentration-dependent titration of pFTAA. 
Non-infected (CD1) and RML6-infected BH were incubated with different concentrations of 
the LCPs as indicated in the Figure and infectivity was determined on 17’000 cells in the 
SCEPA. Each data point represents one sample determined by serial tenfold dilution steps 
from 10-4 to 10-8 on a 96-well plate. Data are shown as mean ± SEM. P-values represent 
statistical difference between LCP-treated and untreated RML homogenates and were 
calculated with a Mantel-Haenszel Chi-square test. n/a: no positive wells were observed with 
this sample between concentrations ranging from 10-3 to 10-8. Part of this analysis was 
performed by Carlo Suter. 
 
A B 
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which corresponds approximately to the amount of PTAA present in the medium used for the 
infection with the RML6 sample treated with 900 µg/ml shown in Figure 26A.                         
After analysing the data in the SCEPA I obtained logID50/g values that did not significantly 
differ (Tables 11 and 12), confirming that the susceptibility of PTAA-treated cells to prion 
infection was not affected. 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Experimental setup for verification of the susceptibility of PK1-N2a cells to RML6 
in the presence of PTAA. 
A serial dilution (shown on the left) of each sample indicated in the figure was investigated (results 
and statistical analysis in Tables 9-12). 
(A) Each sample was first incubated with water or PTAA before addition of a 10-fold excess of 
BH, either non-infectious (CD1 BH 10%) or infectious (RML BH 10%). The infectious titre of 
each sample was then determined according to the normal procedure for SCEPA. 
(B) Cells were plated either in culture medium (upper) or in culture medium containing PTAA 
(lower) 16 hours before addition of a prion-infectious inoculum. The infectious titre of all samples 
was then determined according to the normal procedure for SCEPA. Part of the SCEPA analysis 
was performed by Carlo Suter. 
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Finally, I used an MTA assay to exclude the possibility of acute toxicity of PTAA to N2a PK1 
cells when spiked in the culture medium (Figure 28). A concentration of 50 µg/ml PTAA in 
the culture medium (corresponding to the sample treated with 5000 µg/ml PTAA in Figure 
26A) did not affect cell viability in this paradigm. Therefore I conclude that LCPs can reliably 
decrease prion infectivity of RML6 without affecting the sensitivity of the SCEPA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bioassay in tga20 mice  
Because PTAA-treated RML6 showed a significant reduction in prion infectivity in the 
SCEPA, I next asked whether PTAA-treated RML6 would also affect the survival time of 
tga20 mice, a mouse line that overexpresses wild-type PrP about 10-fold (Fischer et al., 
1996). Therefore, I intracerebrally inoculated 10-fold serial dilutions of untreated or PTAA-
treated RML6 ranging from 10-5 to 10-8 (dilution of wet brain tissue) into tga20 mice (Figure 
29). Mice were observed for clinical signs until they reached the terminal stage of disease. 
The mean survival time for tga20 mice inoculated with an untreated and a PTAA-treated 10-6 
dilution of RML6 was 83 ± 0.5 and 88 ± 13.5 days (n= 5), respectively, indicating a slightly 
prolonged survival time with statistical significance (p = 0.044). There was no statistically 
significant difference between groups of mice inoculated with other concentrations of 
untreated or PTAA-treated RML.  
 
 
Figure 28: PTAA does not provoke 
acute toxicity to n2a cells. 
MTS assay comparing water-treated 
and PTAA-treated RML6. Values are 
indicated as percentage of the negative 
control (water). The positive control 
for toxicity is RML6 treated with SDS 
0.1 % and is set as 100% toxicity on 
the graph. The MTA analysis was 
performed by Carlo Suter. 
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Reactivity of LCP-treated RML6 prions with prion-specific binding 
peptoids  
Because of my finding that LCPs render PrPSc more resistant to PK digestion, I decided to use 
the MPA as a PK-independent tool to further analyse the physical properties of LCP-treated 
prions. I exposed 1% RML6 BH with different concentrations of the LCPs PTAA, POMT, 
pHTAA and pFTAA. I chose to focus on PTAA for its availability in large amounts and 
included POMT because I wanted to investigate a cationic LCP. I also tested the 
monodisperse versions of PTAA: pHTAA and pFTAA because of their ability to cross the 
BBB. Figure 30 show that all four compounds affect the number of PrP aggregates in a dose-
dependent manner. I observed that the treatment of RML6 with 10 µg/ml of the LCPs PTAA, 
POMT and pFTAA significantly reduced the signal in the MPA for RML6 prions (p = 0.004, 
0.015 and 0.003, respectively, Table 13).  PTAA and POMT had the strongest effect at high 
concentrations of 300 and 100 µg/ml, respectively, whereas pFTAA was found to be more 
efficient at lower concentrations. Already the treatment with 1 µg/ml pFTAA caused a 
significant reduction in the MPA signal (p = 0.028). pHTAA appeared to be the less efficient 
compound (Table 14). 
Figure 29: Bioassay in tga20 mice. 
A serial 10-fold dilution of untreated or PTAA-treated RML was inoculated into tga20 mice. The 
curves in red represent the groups inoculated with 10-6-diluted untreated or PTAA-treated RML6. 
*: p = 0.044. Statistical difference was computed using a Log-rank (Mantel-Cox) test. DPI: days 
post inoculation.  
* 
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In order to verify that the LCPs did not affect the assay by unspecific interaction with the 
peptoid-coated paramagnetic beads I performed a control experiment in which I incubated the 
beads with 1 µg/ml PTAA prior to their use. Figure 31 show that pre-treatment of the beads 
with PTAA had no effect on the capture efficiency of untreated or PTAA-treated RML prions 
(Table 15). The MPA data show that the LCPs significantly reduce the number of captured 
aggregates which is in good accordance with the infectivity data obtained in the SCEPA. 
 
 
Figure 30: LCPs reduce the signal for prion aggregates in the MPA. 
Concentration-dependent titrations of the LCPs PTAA, POMT, pHTAA and pFTAA were 
performed on RML6 prions and the reactivity with prion-specific binding peptoids was analyzed in 
the MPA. Each sample was analyzed in technical quadruplicates (circles) and is represented as the 
mean ± SD. All data were corrected for the negative control (mock: CD1 BH) and represented as 
relative light units normalized for the control (untreated RML6 BH). Statistical differences were 
computed to compare LCP-treated RML6 to the control (untreated RML6) (Table 13) or groups of 
four concentrations of each LCP (Table 14). 
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Figure 31: Control experiment for the MPA. 
Paramagnetic beads were treated with 100 µg/ml PTAA or left untreated prior to capture of 
untreated (+H2O) or PTAA-treated uninfected (mock: CD1 BH) or prion-infected (RML BH) 
samples. A significant reduction in the signal could be observed for the negative controls 
(CD1+H2O and CD1+PTAA). This statistical significance can be imputed to the small 
variability between technical replicas for the samples that yielded low fluorescence, and 
therefore is to be considered as a statistical artefact. 
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Conformational stability of PTAA-treated RML prions 
I next investigated whether the LCPs change the biochemical properties of RML prions by 
altering the stability of PTAA-treated RML. I mixed a 1% RML6 BH with two different 
concentrations of PTAA. Untreated and PTAA-treated RML6 was then incubated with 
increasing concentrations of GdnHCl for 60 min, digested with PK to remove soluble PrP and 
analyzed by Western blotting (Thackray et al., 2007). Figure 32 displays that PrPSc in the 
untreated samples remained visible even at a concentration of 3 M GdnHCl, whereas in the 
samples treated with 10 and 100 µg/ml PTAA the signal for PK-resistant material abolished at 
2.4 and 2 M GdnHCl, respectively, indicating that PTAA-treated PrPSc is less stable than 
untreated PrPSc. However, the persistence of higher-order aggregates in all samples treated 
with PTAA suggests that PTAA induces conformational changes of PrPSc that are not affected 
by denaturation with GdnHCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: PTAA-treated RML6 prions are more sensitive to denaturation with GndHCl. 
Immunoblots of untreated (upper panels) and PTAA-treated RML6 BH at different concentrations 
of GdnHCl. RML6 BH was treated with either 10 µg/ml (middle panels) or 100 µg/ml PTAA 
(lower panels). Aliquots of 20 µg protein were denatured with various concentrations of GdnHCl, 
subsequently digested with PK to remove soluble PrP and loaded to the gel. The anti-PrP antibody 
POM1 was used for the detection. Molecular sizes are indicated in kDa. 
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I also compared the stabilities of PrPSc in untreated and PTAA-treated RML6 BH in a PK 
independent manner using the MPA. Untreated and PTAA-treated samples were incubated 
with different concentrations of GdnHCl and the amount of insoluble PrPSc was detected by 
the MPA. RML6 prions treated with PTAA exhibited a lower signal in the MPA at all 
GdnHCl concentrations (Figure 33). The GdnHCl concentrations where 50% of the protein is 
solubilized and 50% is in the pellet fractions were 1.72 M for the untreated samples and 0.31 
M for the PTAA-treated samples. The stability data show that PTAA-treated PrPSc is less 
stable than untreated PrPSc, indicating that PTAA physically alters the conformational 
stability of PrPSc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: PTAA-treated RML6 prions are more sensitive to denaturation with GndHCl. 
MPA of untreated (open circles) and PTAA-treated RML6 BH (filled circles) after denaturation with 
different concentrations of GdnHCl. PTAA was used at a concentration of 10 µg/ml. Each sample 
was analyzed in technical duplicates and is represented as the mean ± SD. All data were corrected for 
the negative control (CD1 BH) and represented as relative light units normalized for RML6 prions. 
Asymptotic curves were fitted to each dataset with the [GdnHCl]½  value at which 50% of the 
molecules are in a soluble fraction and 50% are in a insoluble fraction indicated by a dotted line at 
1.72 M for the untreated and 0.31 M for the PTAA-treated samples. 
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PTAA-treated recPrP fibers are more resistant to PK digestion  
In order to investigate the mechanism of action of the LCPs, I asked, in collaboration with Dr. 
Simone Hornemann and Cinzia Tiberi, whether PTAA inhibits amyloid fiber formation of the 
recombinant mouse prion protein mPrP(23-231). Monomeric mPrP(23-231) was grown under 
slightly denaturating conditions according to a protocol published by Apetri and Surewicz in 
the presence of different concentrations of PTAA. The time course of fibrillisation was 
followed by optical density measurements at 350nm for 48h (Apetri et al., 2005). mPrP(23-
231) formed amyloid-like fibrils by a  nucleation-dependent polymerisation with a lag-phase 
followed by an exponential growth phase and a plateau phase (Figure 34A). The addition of 
PTAA significantly reduced the growth rate of the fibers in a dose-dependent manner (Figure 
33A). The incubation with the highest dose of 50 µg/ml resulted in a complete inhibition of 
fiber formation. We further analysed the samples by negatively-stained transmission electron 
microscopy (TEM) (Figure 34B). Electron micrographs of samples withdrawn after 48h 
showed that the untreated control samples contained long unbranched fibers. Fibrils grown in 
the presence of PTAA at concentrations between 1 and 10 µg/ml were coated with small 
PTAA aggregates in a regular and periodic manner (Figure 34D, E and F), suggesting a 
specific binding of PTAA to the fibers. With increasing PTAA concentrations we also 
observed coalescence of the fibers and fiber formation was inhibited (Figure 34B), as 
evidenced by empty EM grids at PTAA concentrations above 25 µg/ml. Next, we asked 
whether PTAA directly interacts with preformed mPrP(23-231) fibers. For that purpose, we 
incubated fibers that were grown for 48h with different concentrations of PTAA and analysed 
their morphology by TEM. Electron micrographs showed that fibers incubated with PTAA 
concentrations between 1 and 10 µg/ml were also associated with small aggregates of PTAA 
as seen for the fibers grown in the presence of PTAA (Figure 34C, D and E). With increasing 
PTAA concentrations we observed a coalescence of the fibers (Figure 34C), resulting in large 
associations of the fibers. To determine whether PTAA also renders mPrP(23-231) fibers 
more resistant to PK digestion, I incubated mPrP(23-231) fibers with 10 µg/ml PTAA and 
performed a limited proteolysis with different PK concentrations. Figure 34G shows that 
PTAA-treated fibers are more resistant to PK digestion than untreated fibers as already seen 
for LCP-treated RML6 prions. Our data show that PTAA inhibits mPrP(23-231) fiber 
formation and directly interacts with the fibers, causing a coalescence of the fibers into more 
compact structures upon treatment with PTAA which are also more PK resistant. 
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Figure 34: Effect of PTAA on mPrP(23-231) fiber formation and preformed fibers. 
(A) Time course of mPrP(23-231) fiber formation grown in the absence (filled circles) and 
presence of PTAA at different concentrations of 5 µg/ml (open circles), 10 µg/ml (filled squares), 
25 µg/ml (open squares) and 50 µg/ml (filled diamonds) followed over a period of 48h. Error bars 
represent the SEM of technical triplicate measurements. (B) TEM taken after 48h of control fibers 
grown in the absence of PTAA and of fibers grown in the presence of different concentrations of 
PTAA. (C) TEM of preformed mPrP(23-231) fibers incubated with different concentrations of 
PTAA. The electron micrograph in the right lower corner displays the fibrils incubated with 1 
µg/ml PTAA at higher magnification. (D) TEM of fibers recorded from another independent 
experiment grown in the presence of 10 µg/ml PTAA (upper panel) and of preformed mPrP(23-
231) fibrils mixed with 1 µg/ml PTAA (lower panel). (E) PTAA formed two different populations 
of small aggregates at concentrations between 1 and 10 µg/ml which bound to the fibers with mean 
diameters of 43.9 ± 2.5 (bound P1) and 16.8 ± 2.8 (bound P2). Free aggregates had mean diameters 
of 25.6 ± 7.4 for population 1 (Free P1) and 15.4 ± 2.8 (Free P2). Data are represented as the mean 
± SD. (F) PTAA aggregates were located on the fibers in a periodic manner with distances of 42.2 
±12.5 nm for population 1 and 36.3 ± 8.6 nm for population 2. Data are represented as the mean ± 
SD. (G) PTAA increases the resistance of mPrP(23-231) fibers to PK digestion. Aliquots of 
mPrP(23-231) fibers were incubated with 10 µg/ml PTAA prior to proteolysis with increasing 
concentrations of PK. Lane 1 contains non-digested mPrP(23-231) fibers. Scale bar: 100 nm. 
Molecular sizes are indicated in kDa. 
Simone Hornemann performed all work shown in Figure 34A to 34F and prepared the Figure. 
Cinzia Tiberi performed part of the TEM analysis. Ilan Margalith performed experiments shown in 
Figure 34G. 
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DISCUSSION 
The high degree of steric specificity of the interaction of LCPs for amyloids had previously 
been evidenced in the context of the structural differentiation of prion strains (Sigurdson et 
al., 2007). In addition, LCPs decreased PrPSc levels in chronically prion-infected 
neuroblastoma cells (N2a) (Julius C., K. Peter R. Nilsson, not shown), a result similar to the 
observation made by Caspi et al. with CR. I therefore decided to investigate the potential of 
LCPs for interfering with stability of PrPSc and the release of prion infectious particles. 
Preliminary data from immunoblots of COCSBH from cultures treated with PTAA or PBAT 
revealed more PK-resistant material and increased presence of higher-order aggregates. These 
observations suggest a structural modification of prions present at the time of treatment 
initiation and/or prion replicating during the course of the experiment into a more PK-resistant 
form. If more compact, such aggregates would also be more stable and therefore less prone to 
release prion infectivity. As PK-resistant material is only a surrogate marker for prion 
accumulation I measured the infectivity titre of COCSBH in the SCEPA. Cultures treated 
with 6 µg/ml PTAA had lower infectivity titres than untreated cultures at 42 DIV. The 
efficiency of treatment with 6 µg/ml PTAA was comparable to that of 0.3 µg/ml PPS. I have 
excluded the possibility that PTAA accumulated in cultured tissue could affect the 
measurement of prion infectivity and therefore conclude that my observations reflect a 
decrease of prion accumulation in PTAA-treated slice cultures and/or a structural change of 
pre-existing prions into entities that are less infectious. In addition, treatment with 60 µg/ml 
PTAA decreased infectivity of COCSBH below the level measured at the time of treatment 
initiation. This further point towards a structural change, upon PTAA treatment, of pre-
existing prions into a form that is less prone to release prion infectious particles. 
To further investigate a possible change in prion load in COCSBH I measured prion 
aggregates in the MPA. This method does not imply digestion with PK and may therefore 
better reflect prion content. Cultures treated with 0.1 to 60 µg/ml PTAA had lower reactivity 
with prion-specific binding peptoids than untreated tissue at 42 DIV. This may reflect either a 
decreased prion load, a structural shift of prions towards larger aggregates that offer less 
binding surface to prion-specific binding peptoids or a partial disaggregation of prions by 
PTAA. In addition, the presence of prion aggregates in the MPA correlated remarkably well 
with the measurements of prion infectivity in the SCEPA and suggests that these two methods 
are measuring the same entities. To explore the discrepancy between the observation of 
increased PK-resistant material and higher-order aggregates shown by Western blot and the 
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decreased prion content evidenced by SCEPA and MPA, I further investigated PK-resistant 
material in COCSBH by using an ELISA for PK-resistant PrP. PTAA-treated cultures had 
less PK-resistant material than untreated cultures when measured by ELISA. These results are 
perfectly in line with the parallel observations of decreased prion infectivity in the SCEPA 
and decreased prion aggregates in the MPA and further point towards a decreased prion load 
in PTAA-treated tissue. Of note, a good correlation between the entities measured by MPA, 
SCEPA and ELISA indicates that the same entity is being affected by PTAA which results in 
a decrease of measurable PrPSc aggregates and infectivity. In addition, histoblots from tissue 
cultured and treated in a similar manner revealed decreased accumulation of PK-resistant 
PrPSc in PPS or PTAA-treated tissue. I therefore conclude that PTAA-treated COCS have a 
decreased prion content compared to untreated tissue. I cannot exclude, however, that PTAA 
induced a structural shift of prions. The discrepancy between PK-resistant material observed 
by Western blot and ELISA could be due to an interaction of PTAA with prions that renders 
them more impervious to PK. As I have shown that guanidine reverses the effect of PTAA, it 
is possible that PrPSc investigated by WB was in a more compact state that was unfolded by 
the guanidine used in the ELISA protocol. Treatment with 60 µg/ml PTAA resulted in a prion 
load of COCSBH that lies below that of tissue harvested at 21 DIV. In this particular case, 
PK-resistant material evidenced by Western blot correlated with that shown by ELISA. 
Furthermore, the signal in the MPA and the prion infectious titre of these cultures were also 
lower than at 21 DIV. These results may reflect a PTAA-induced partial disaggregation of 
prions present at the time of treatment initiation or a facilitated removal of such prion levels 
by scavenging cells. Alternatively it could be due to a structural change of pre-existing prions 
into a form that is less PK-resistant, less prone to reactivity with prion-specific binding 
peptoids and releases less infectivity. This would be explained by an enhanced compactness 
of prion aggregates. In addition, I performed PTAA treatment in a time-resolved manner and 
investigated prion load by MPA and ELISA. This analysis revealed that PTAA treatment is 
most effective if initiated before 21 days post-infection. PTAA treatment started at 28 or 35 
DIV resulted in an amount of PK-resistant material that was respectively similar or lower than 
at the time of treatment start and further indicates that PTAA interferes with prion replication 
within the tissue and possibly transforms pre-existing prions into a form that is less efficiently 
detected by my methods. In addition, the analysis of this experiment by MPA and ELISA in 
parallel shows that the measurement of prion aggregates with prion-specific binding peptoids 
may not be an appropriate method in this particular paradigm, as the MPA could not detect 
prion aggregates in COCSBH from PTAA-treated cultures. It is possible that the proximal 
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coating of prion fibrils by PTAA interferes with the interaction of peptoids with binding sites 
on prion aggregates. Alternatively, it is possible that PTAA interaction with prion aggregates 
results in a structural change of the latter towards larger structures that offer less interacting 
surface with peptoid-coated beads. As the interaction of PTAA with RML prions or with 
recPrP fibril seeds was recently shown to block, respectively, the release of prion infectivity 
and the fibrilization of murine recPrP (Margalith et al., 2012), it is possible that prion 
replication within the tissue was impaired by PTAA. It is not clear, however, how this anti-
prion seeding effect would be achieved. PTAA could either induce a structural shift towards a 
more compact, more stable form or on the contrary induce a partial disaggregation of prions. 
My observations are compatible with both views, to the condition that in the case of a partial 
disaggregation, PTAA would additionally protect the POM1 epitope from PK, which would 
explain the observation of increased PK-resistant material by immunoblotting. 
My results show that the interaction of PTAA and its derivatives with prion containing BH 
significantly reduced prion infectivity in the SCEPA. An apparent complete removal of prion 
infectivity was only achieved at high concentrations of PTAA, however the use of other LCPs 
show that these molecules generally decrease prion infectivity even at low concentrations. I 
also performed a titration of infectivity of PTAA-treated RML in tga20 mice to investigate 
whether PTAA prolongs the survival time. As I only saw a weak difference, I believe that the 
SCEPA is a stronger tool for measuring variations in prion infectivity: Indeed, prions injected 
in vivo, even if less able to release infectious particles upon PTAA treatment, would remain in 
the brain for a long time. By contrast, the cells used in the SCEPA are only exposed to prion-
containing samples for a short period and therefore may reflect better the release of prion 
infectivity.  
To elucidate the mechanism underlying the above-described phenomena I characterized the 
influence of LCPs on the resistance to proteolysis of RML prions in a crude brain 
homogenate. My results show a profound increase in the apparent signal for PK-resistant 
material on a Western blot of RML prions. Importantly, PK digestion was not affected, as all 
PK-sensitive PrP was removed and the products of cleavage appeared identical in treated or 
untreated RML, suggesting that the discrete conformation of PrPSc was not changed. 
However, the observation of higher-order aggregates suggests structural changes at the level 
of the quaternary structure of aggregates in LCP-treated, PK-digested RML prions. Notably, 
the decoration with PTAA of recPrP fibrils also resulted in improved resistance to PK 
digestion and electron micrographs revealed coalescence of PTAA-coated recPrP fibrils into 
more compact structures. Of note, PTAA interacted as small aggregates in a periodic manner 
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with recPrP fibrils, which underlines the specificity of PTAA for amyloid structures. In 
addition, all LCPs that decreased prion infectivity also increased the apparent amount of PK-
resistant material of RML and PTAA interfered with fibrilization of recPrP, which supports a 
link between modified infectivity and possible structural changes of associated aggregates. 
The antiprion activity of LCPs cannot be attributed to the charges of their side chains, since 
anionic, cationic and zwitterionic compounds reduced prion infectivity to a similar extent. 
Also, neither the spacing between the side chains nor the rigidity of the molecules seemed to 
play a role for their antiprion activity. Based on theoretical considerations, the total avidity of 
LCPs for amyloids should increase with the number of low-affinity binding sites, and 
therefore with the length of the polymers. However, very long polymers may have chemical 
properties limiting their interactions. Hence the activity of LCPs appears to be an intrinsic 
property of the polythiophene backbone itself. PTAA also caused a left-shift in the 
conformational stability curve of PrPSc after exposure to increasing concentrations of the non-
surfactant-type chaotrope, GdnHCl. Coalescence of fibrils into more compact structures is not 
necessarily incompatible with increased denaturation by guanidine: as PK resistance was 
suggested to depend on conformational state of PrP (Jackson et al., 1999) it is possible that 
LCP coating of prions results in a perturbation of the structure of aggregates which may create 
nuclei that are more impervious to PK digestion, yet these nuclei may still be permissive to 
denaturation by guanidine. In addition, the persistence of higher-order aggregates in PTAA-
treated, denatured, PK-digested RML prions suggest that not all of the structural changes 
induced by PTAA are reversed by denaturation. To further investigate possible structural 
changes of LCP-treated prions, I used the MPA, an assay which is independent of PK 
digestion. I observed a good correlation between decreased prion infectivity and decreased 
signal for prion aggregates in the MPA. This could be due to a coalescence of RML prions 
into larger structures that are less prone to release prion infectious particles, which would fit 
to a proposed model in which fibril fragility determines nucleation and further fibril 
elongation (Knowles et al., 2009). It cannot be excluded, however, that the MPA may be 
affected by a competition of the LCPs with peptoids for binding sites on prion aggregates. In 
this study the MPA provided an independent confirmation of structural changes linked with 
decreased infectivity provoked by an anti-prion compound, in a PK-independent manner. This 
is interesting because sensitivity of treated prions to PK is not always reliable and therefore 
might be misleading for testing of therapeutic compounds. I therefore propose to use the MPA 
as a fast method for the detection of prions and a high throughput assay to screen for novel 
drugs. 
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LCPs may act on prion species in different way. PrPSc was more resistant to PK digestion with 
low concentrations of the LCPs, which also induced the formation of SDS-stable high-
molecular-weight aggregates. Accordingly, PTAA transformed recPrP fibers into more 
compact structures. Very high concentrations of PTAA and POMT, however, decreased the 
resistance of PrPSc to PK. These adverse effects resembles the mechanisms reported for 
several surfactants which were assumed to affect protein aggregation in a two-concentration 
dynamic by either interacting as monomers or in equilibrium with small molecule aggregates 
(Otzen, 2010) and were demonstrated to enhance or reduce the stability and detectability of 
PK resistant PrPSc (Caspi et al., 1998; Milhavet et al., 2000; Breyer et al., 2012). A similar 
mode of action was reported for CR which induces β-sheet formation and self-propagation of 
monomeric Aβ (Lendel et al., 2010; Abelein et al., 2012). LCPs might promote de novo PrP 
aggregation by converting PrP into compact aggregates that are more resistant to PK but less 
infectious. Accordingly, LCPs used at low concentrations (at which the effects cannot be 
attributed to micelle formation) may prevent prion replication by stabilizing the PrPSc 
conformation, which may resultin reduced fiber frangibility, a critical determinant of prion 
infectivity (Caughey and Lansbury, 2003; Knowles et al., 2009) which controls prion 
propagation by fragmentation of fibrils and elongation of these infectious particles into new 
fibrils (Wang et al., 2011). The denseness of LCP-treated PrPSc aggregates may reduce the 
release of infectious seeds, resulting in decreased prion infectivity. This possibility is 
supported by studies showing uncoupling of aggregates size and infectivity (Gabizon et al., 
1987; Silveira et al., 2005; Tixador et al., 2010). In conclusion, LCPs can be protective by 
stabilizing non-compact fibrils. It is also possible that pre-existing prions, and possibly also 
PrPC, are included into inert structures (Figure 35, Adapted from: (Margalith et al., 2012)). 
 
 
 
 
 
 
 
 
 
 
 
                    RESULTS
 _____________________________________________________________________ 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some studies have shown that larger polymers were more PK-resistant than smaller ones 
(Sklaviadis et al., 1992; Pastrana et al., 2006). Also it has been demonstrated that prion strains 
with short incubation times had infectivity peaking in the upper part of the sedimentation 
profile when the respective brain homogenates were subjected to centrifugation in a viscous 
medium (Tixador et al., 2010), which suggests a link between small forms of PrPSc and 
infectivity. My results support this view: LCPs trigger a shift in the size distribution of 
aggregated recPrP that correlates with increased resistance to PK. PTAA-treated RML prions 
Figure 35: Model for the antiprion activity of the LCPs. Adapted from: (Margalith et al., 2012). 
(A) In the prion model PrPC is in a reversible thermodynamic equilibrium with PrP*, which further 
aggregates into amyloid fibrils, PrPSc. When the fibrils reach a critical length, the fibril becomes more 
fragile and fragmentation occurs. The newly formed ends of the fibril fragments are new nucleation sites 
for further fibril growth. 
(B) The antiprion activity of the LCPs seems to be based on interactions with PrPSc aggregates, possibly 
increasing their compactness. LCP coated fibrils further embed preexisting prions and even PrPC. The 
higher compactness of the PTAA treated aggregates ultimately cause less fragmentation into infectious 
particles necessary for further prion replication. 
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also had more PK-resistant material, were less infectious, and had a decreased signal in the 
MPA that could be interpreted as a decreased binding surface to peptoids of larger prion 
aggregates. However, this decrease of signal in the MPA could also be interpreted as a partial 
disaggregation into smaller PrP aggregates. This scenario may fit better with the apparent loss 
of conformational stability and loss of reactivity in the MPA, however in this paradigm it 
would be difficult to interpret the increased resistance to PK and higher-order aggregates. 
Also, disaggregation would rather be expected to increase infectious seeds. 
Prions are defined by biochemical and biological parameters such as resistance to proteolysis 
and prion infectivity and the observation of protease-resistant material tends to correlate with 
prion infectious titres (Safar et al., 1993). Some experiments, however, have shown that not 
always a clear correlation between PK resistance and infectivity exists (Sklaviadis et al., 
1989; Hsiao et al., 1994; Lasmezas et al., 1997; Shaked et al., 1999; Chiesa et al., 2003; 
Barron et al., 2007; Piccardo et al., 2007), which points out that PK-resistant material is a 
surrogate marker for infectivity. The observation of increased PK-resistant material and 
decreased prion infectivity in this study is a rather unexpected finding since anti-prion 
compounds rather induce a disruption of PrPSc which should therefore be more sensitive to 
PK digestion. Therefore, I conclude that the use of PK digestion only for evaluation of anti-
prion compounds may be misleading. 
Although the results presented in this thesis underline that LCPs can interact with PrPSc, their 
effects on COCS suggest that they may act as well during the transformation of PrPC to PrPSc. 
ELISA measurements on COCSBH showed that the PrPC content was reduced approximately 
two-fold, suggesting that PTAA might remove PrPC from the cell surface or modulate PrPC 
levels. This may reduce the amount of PrPC available for the formation of PrPSc. A similar 
mechanism was reported for other antiprion compounds (Shyng et al., 1995; Pauly and Harris, 
1998; Milhavet et al., 2000; Enari et al., 2001; Peretz et al., 2001; Brown and Harris, 2003; 
Hijazi et al., 2003; Perrier et al., 2004). This interpretation is supported by my finding of a 
direct interaction of PTAA with PrPC evidenced by an in vitro conversion assay with recPrP 
in the presence of PTAA in a cell-free environment. PTAA strongly inhibits the formation of 
recPrP fibers, supporting that it directly interacts with PrPC by either stabilizing the spatial 
conformation of PrPC or protecting the binding site for the template PrPSc molecule. Both 
effects may prevent efficient convertion of PrPC into PrPSc. 
In conclusion, LCPs triggers a structural transformation of PrPSc in by a mechanism that 
resembles the one of surfactants. This process depends essentially of the LCP backbone and 
not on the nature of the side-chains. PrPSc becomes more resistant to PK digestion upon 
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incubation with LCPs, while proteolysis of PrPC and other proteins is not affected, and 
strongly decreases prion infectivity. This body of data also links decreased infectivity to 
formation of more stable PrPSc species. Therefore, the LCP scaffold may be used to generate a 
promising new family of antiprion compounds. The recently developed LCPs, pHTAA and 
pFTAA, were shown to penetrate the BBB (Aslund et al., 2009) and may represent good 
candidates for further investigation and for in vivo studies. 
OUTLOOK 
Further biochemical studies aimed at better defining structure of LCP-treated prions, such as 
field-flow fractionation, would help elucidate the structural changes that are responsible for 
the decrease of prion infectivity shown in this study. In addition, the potential of LCPs for 
curing prion diseases must be investigated in more detail in vivo. To that effect, a project has 
been started in the laboratory of Prof. A. Aguzzi involving delivery of LCPs to mice through 
osmotic pumps. 
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MATERIAL AND METHODS PART I 
Preparation of CD1 and RML6 crude brain homogenate 
20% wt/vol RML6 or CD1 brain homogenates in 0.32M sucrose in PBS were prepared by 
three runs in a PreCellys tissue homogenizer with cooling on ice between each run. Protein 
concentrations of RML6 or CD1 brain homogenates were determined using the bicinchoninic 
acid assay (Pierce) and normalized to 1 mg/ml total protein with 0.32M sucrose in PBS. 
Preparation of LCP stock solutions 
The synthesis of the different LCPs has been described elsewhere (Ding et al., 2000). 
Lyophilized LCPs were resuspended in pure water (B.Braun, Melsungen AG) and stock 
solutions at a concentration of 1 mg/ml were prepared and stored at 4°C, protected from light. 
Serial dilutions of the LCPs were prepared in pure water. 
Treatment of slice cultures with LCPs 
Cerebellar slice cultures were prepared and prion-infected according to Falsig et al. Slice 
culture medium was changed three times per week and 10 µl of diluted LCP or PPS (30 µg 
ml-1, Bene pharmachem) was added to 1 ml medium to obtain final concentrations ranging 
from 0.01 µg/ml to 60 µg/ml PTAA or 0.3 µg ml-1 PPS. Treatment was initiated three weeks 
post-infection or in a time-course manner and maintained until tissue was harvested. 
Preparation of slice culture homogenates 
Tissue was harvested in PBS and homogenized according to Falsig et al in PBS. Protein 
concentration was determined using the bicinchoninic acid assay (Pierce) and normalized to 1 
mg/ml total protein with PBS. 
Quantification of total protein from slice culture homogenates 
A BCA Protein Assay Kit was used according to the manufacturer`s protocol (23-225 BCA™ 
Protein Assay Kit, Pierce) for quantification of total protein from 1% slice culture 
homogenates. 
Proteolysis of COCSBH and Western blot analysis 
PrPSc was detected by limited proteolysis with proteinase K (PK) (Roche) and analysed by 
Western blotting. 20 µg protein aliquots were digested with 25 µg/ml PK in lysis buffer 
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containing 0.5% wt/vol sodium deoxycholate, 0.5% vol/vol Nonidet P-40 and 10% vol/vol 
PBS for 60 min at 37°C and rotating at 700 rpm on a thermoshaker in a total volume of 20 µl. 
This condition allowed specific detection of PrPSc. PK digestion was terminated by adding 6.7 
µl of 4x LDS loading buffer (NuPAGE, Invitrogen) and boiling the samples at 95 °C for 5 
min. 20 µl of the samples were separated on a 12% Bis-Tris SDS polyacrylamide gel 
(NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. Membranes were blocked 
with 5% wt/vol Topblock (Fluka) in Tris-buffered saline supplemented with Tween (150 mM 
NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) and incubated with POM1 (Polymenidou 
et al., 2005) mouse IgG1 antibody to PrPC (anti-PrPC) (200 ng/ml) as primary antibody. Horse 
radish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, Zymed) was used as a 
secondary antibody. The blots were developed using SuperSignal West Pico 
chemiluminescent substrate (Pierce) and detected in a LAS3000 system (FUJI). 
Scrapie Cell End-Point Assay of COCSBH 
COCSBH normalized to 1 mg/ml total protein was diluted 1 to 100 fold in cell culture 
medium to obtain a final dilution of 10-4 from full brain. These samples were then serially 
diluted in cell culture medium containing a 10-4 dilution of CD1 BH and dilutions of 
COCSBH ranging from 10-4 to 10-8 were tested in 96-well plates. Experimental runs 
comprised 4 plates including a COCSBH from six weeks-old prion-infected, untreated tissue 
as a standard plate. The infection of N2a-PK1 cells and subsequent processing of the SCEPA 
were performed as previously described (Klohn et al., 2003). 
Misfolded protein assay 
10 µg total protein (BH or COCSBH prepared as 1% w/v in 0.32 M sucrose in PBS and 
normalized to 1 mg/ml) was diluted 100 fold in TBSTT [50 mM Tris-HCl (pH 7.5)/137 mM 
NaCl/1% Tween 20/1% Triton X-100] and incubated 10 min at 37 °C under permanent 
agitation (850 rpm). 100 µl was then subjected to precipitation using magnetic beads coupled 
to the peptoid PSR1 (Lau et al., 2007) for 1 h at 37 °C under permanent agitation (750 rpm). 
Beads were washed and trypsin digestion was performed (12.5 µg/ml trypsin in TBST 
containing 5 mM CaCl2) for 30 min at 37 °C under permanent agitation (750 rpm) and 
stopped with 2 mM PMSF for 15 min at RT. Beads were washed and denatured with 0.1 N 
NaOH. After neutralization (0.3 M Na2H2PO4), samples were placed on a magnet, and 
supernatant was transferred to POM19 (Polymenidou et al., 2005)-coated ELISA plates. After 
incubation (1 h at 37°C, 300 rpm), plates were washed, and POM2-AP (Polymenidou et al., 
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2005) was added. After incubation with substrate (100 μl of Lumiphos Plus substrate 
(Lumigen, Southfield, MI), plates were read in a luminometry reader (Luminoskan Ascent; 
Thermo Fisher Scientific). 
ELISA 
For ELISA, COCSBH were diluted ten-fold in TBSTT [50 mM Tris-HCl (pH 7.5)/137 mM 
NaCl/1% Tween20/1% Triton X-100] to obtain a final concentration of 0.1 mg/ml total 
protein. Digestion with proteinase K (PK) was performed in a 96-well plate for 60 min at 37 
°C, rotating at 700 rpm on a thermoshaker in a total volume of 50 µl containing 50 µg ml-1 
PK. Digestion was halted by adding 2 mM phenylmethanesulfonylfluoride (PMSF, 
Calbiochem) and Complete Mini protease inhibitor cocktail (Roche). Digested samples were 
denatured with an equal volume of 3 M GdnSCN for 30 min at 37 °C and diluted with four 
volumes of 0.1 M NaHCO3 pH 8.9. The samples were then detected by sandwich ELISA. 
Briefly, ELISA plates were coated with POM1-antibodies (400 ng/well) in coating buffer 
overnight. After washing with PBST, plates were blocked with blocking buffer (5% TopBlock 
in PBST) for 2 hrs at room temperature. Next, samples were incubated for 2 hours on ELISA 
plates (Nunc, MaxiSorb). Captured samples were detected with POM19 antibody (1 mg/ml, 1 
hour, diluted in sample buffer) and horse radish peroxidase (HRP)-avidin conjugate (1 mg/ml, 
1 hour, diluted in sample buffer) (BD Pharmingen). Samples were analysed by ELISA in 
technical triplicates and washed five times with PBS 0.05% Tween20 between each antibody 
and conjugate incubations. Finally, TMB substrate (Invitrogen) was added to the wells and 
incubated for 15 min at room temperature and stopped by adding 0.5 M H2SO4. The 
absorbance was read at 450 nm in a VERSAmax microplate reader and validated with the 
SOFTmax PRO software. 
Histoblots of slice cultures 
The histoblot technique was performed according to previously published protocols 
(Taraboulos et al., 1992) with the following modification for slice cultures: 100% Ethanol-
fixed slice cultures of various thicknesses comprised between 50 and 300 µm were pressed on 
a nitrocellulose membrane wetted in lysis buffer. Membranes were air-dried for at least 24 h. 
For detection, they were rehydrated in TBST, and limited proteolysis was performed using 
proteinase K concentrations of 0, 20, 50 and 100 µg/ml in digestion buffer at 37 °C for 4 h. 
Blots were washed three times in TBST, denatured in 3 M guanidinium thiocyanate for 
10 min, washed another three times in TBST and blocked for 1 h in 5% non-fat milk in TBST. 
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Incubation with primary antibody POM1 was carried out at a dilution of 1:10000 in 1% non-
fat milk in TBST at 4°C overnight. Blots were washed three times in TBST and blocked for 5 
min in 1% non-fat milk in TBST. Detection was accomplished by adding an alkaline 
phosphatase-conjugated goat anti-mouse antibody (Dako D0486) at a concentration of 1:2000 
for 1 h. Blots were washed three times in TBST and B3 solution (100 mM Tris, 100 mM 
NaCl, 100 mM MgCl2, pH 9) was applied for 10 min. Visualization was achieved with nitro 
blue tetrazolium and bromo-chloro-indolyl phosphate solution (Roche) (1 tablet for 10 ml 
water and 10 µl 1M Levamisole) for 45 min and washing with B4 solution (100 mM Tris, 
0.01 mM EDTA, pH 8) for 30 min. 
Immunohistochemistry 
For immunocytochemistry of in vitro material, the organotypic slice cultures were washed 
twice in PBS and fixed in 4% formalin overnight at 4 °C. Membrane inserts were washed and 
incubated for 1 h in blocking buffer (0.05% vol/vol Triton X-100 and 3% vol/vol goat serum 
dissolved in PBS) and incubated with the primary antibody diluted in blocking buffer at 4 °C 
for 3 days. The primary antibody mouse anti-Neuronal Nuclei (NeuN, 1 μg ml-1, Serotec) was 
detected using the Alexa-conjugated secondary antibody Alexa Fluor 647 (3 µg ml–1, 
Molecular Probes) and counterstained with 4,6-diamidino-2-phenylindole (dapi) (1 µg ml–1). 
Images were recorded at 4x magnification on a fluorescence microscope (BX-61, Olympus) 
equipped with a cooled black/white CCD camera. 
Treatment of RML prions with LCPs 
LCPs were diluted into aliquots of normalized crude brain homogenates at final 
concentrations ranging from 0.1 µg/ml to 5000 µg/ml and to final volumes of 45 µl. All 
samples were incubated for 30 min at 37°C on a thermo shaker rotating at 700 rpm prior to 
proteolysis. 
Proteolysis of RML6 prions and Western blot analysis 
PrPSc was detected by limited proteolysis with PK (Roche) and analysed by Western blotting. 
45 µl samples were digested with 50 µg/ml PK in lysis buffer containing 0.5% wt/vol sodium 
deoxycholate, 0.5% vol/vol Nonidet P-40 and 10% vol/vol PBS for 60 min at 37°C and 
rotating at 700 rpm on a thermoshaker. This condition allowed specific detection of PrPSc. PK 
digestion was terminated by adding 17 µl of 4x LDS loading buffer (NuPAGE, Invitrogen) 
and boiling the samples at 95 °C for 5 min. 30 µl of the samples were separated on a 12% Bis-
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Tris SDS polyacrylamide gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose 
membrane. Membranes were blocked with 5% wt/vol Topblock (Fluka) in Tris-buffered 
saline supplemented with Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 
(vol/vol)) and incubated with POM1 mouse IgG1 antibody to PrPC (anti-PrPC) (200 ng/ml) as 
primary antibody. Horse radish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 
(1:10,000, Zymed) was used as a secondary antibody. The blots were developed using 
SuperSignal West Pico chemiluminescent substrate (Pierce) and detected in a LAS3000 
system (FUJI). 
Scrapie Cell End-Point Assay of BH 
RML samples consisting of 1% BH containing water or various concentrations of 
polythiophenes were diluted 1 to 100 fold in cell culture medium to obtain a final dilution of 
10-4 (dilution of wet brain tissue). These samples were then serially diluted in cell culture 
medium containing a 10-4 dilution of CD1 brain homogenate and dilutions of RML ranging 
from 10-4 to 10-8 were tested in 96-well plates. The effect on RML of 3 dilutions of a 
polythiophene, or 3 different polythiophenes were compared to a standard plate (RML + 
water) in experimental runs that comprised 4 plates. The infection of N2a-PK1 cells and 
subsequent processing of the SCEPA were performed as previously described (Klohn et al., 
2003). 
MTS assay 
We used the MTS assay kit from PROMEGA according to the instructions given by the 
manufacturer. 
Bioassay in tga20 mice 
A 2% (w/v) RML6 brain homogenate was prepared by dilution of a 20% stock with 0.32M 
sucrose in PBS and divided into two 25 µl aliquots. These aliquots were supplemented with 
25 µl PTAA (20 µg/ml) or with water, yielding 1% brain homogenates containing either 10 
µg/ml PTAA or no PTAA and incubated on a thermo shaker for 60min at 37°C, 700 rpm. The 
samples were then further diluted 100 fold with pure water and 10 fold with PBS, yielding a 
10-5 dilution (from full brain). Further 10-fold dilutions of these samples in PBS were 
prepared to inoculate mice with 10-6, 10-7 and 10-8 dilutions. tga20 mice were maintained 
under specific pathogen-free (SPF) conditions. Housing and experimental protocols were in 
accordance with the Swiss Animal Protection Law and mice were held in compliance with the 
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regulations of the Veterinäramt, Kanton Zürich. Mice were intracerebrally (i.c.) infected with 
30 µl of the above-described samples. Numbers of mice inoculated with each dilution is 
indicated in Figure 29. The mice were then monitored three times per week from the 
apparition of the first signs of disease. Mice were then sacrificed at terminal stage of prion 
disease as follows: a sagital section of the brain was fixed in 2% parafomaldehyde for 
immunohistochemistry. From the second half of the brain, a coronal section was snap-frozen 
in HANKS medium for histoblot analysis. The remaining brain material was snap-frozen and 
stored for further biochemical analysis. 
Conformational stability assay of RML6 prions  
Aliquots of RML brain homogenates normalized to 2 mg/ml protein were prepared and water 
or PTAA was added to obtain final concentrations of 0, 10 or 100 µg/ml PTAA before 
incubation for 30 min at 37°C on a thermo shaker rotating at 700 rpm. These samples were 
divided into 10 µl aliquots containing 20 µg protein and an equal volume of water or 2x 
concentrated guanidine were added to obtain the final concentrations indicated in the figures. 
Denaturation was performed by incubating the samples for 10 min at room temperature. For 
Western blot analysis these samples were digested with PK (15 µg/ml) and 20 µl of the 
samples were separated on a 12% Bis-Tris SDS polyacrylamide gel (NuPAGE, Invitrogen) 
and blotted onto a nitrocellulose membrane. For MPA analysis, denaturated aliquots from the 
preparations containing 0 or 10 µg/ml PTAA were diluted 1:100 fold in TBSTT prior to 
capture with peptoid-coated beads in the MPA. 
Preparation of recombinant mouse mPrP(23-231) and conversion into 
fibers 
Recombinant mouse PrP comprising residues 23-231 was expressed and purified as described 
elsewhere (Zahn et al., 2000; Lysek and Wüthrich, 2004; Hornemann et al., 2009). mPrP(23-
231) fibers were produced by incubating the protein at 37 ºC for 48 hours in 50 μM Tris-HCl, 
1 M GdnHCl, 150 mM sodium chloride, pH 7.5, and shaking at 600 (Apetri et al., 2005). To 
study the inhibition of fiber formation by PTAA, mPrP(23-231) fibers were grown in the 
absence and presence of different concentrations of PTAA ranging from 1 µg/ml to 50 µg/ml. 
The time course of fiber formation was followed by measuring the optical density at 350nm 
with a Tecan Saphire 2 plate reader. After 48h the samples were also analysed by 
transmission electron microscopy (see below). Preformed fibrils were mixed with PTAA at 
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concentrations of 10, 25, 50 and 100 µg/ml PTAA for 30 min at 37°C and 600 rpm before 
they were analysed by transmission electron microscopy as described below. 
Transmission electron microscopy 
Carbon coated copper grids were placed on 10 µl of the fibril solutions and incubated for 1 
min. After removing of excess liquid, grids were washed three times with water prior to 
staining with 2% aqueous uranyl acetate for 1 min. Samples were analysed on a Philips CM12 
electron microscope (transmission electron microscope with an acceleration voltage of 80 
keV). 
Proteolysis of mPrP(23-231) fibrils in the presence of PTAA 
mPrP(23-231) fibrils were incubated in the absence and presence of 10 µg/ml PTAA at 37°C 
for 60 min on a thermo shaker rotating at 700 rpm. 18 µl of untreated and PTAA-treated 
recPrP fibrils were digested with PK at concentrations of 0.5, 1, 1.5 and 2 μg ml−1 diluted in 
PBS at 37°C for 60 min on a thermo shaker rotating at 700 rpm. PK digestion was terminated 
by adding 7 µl of 4x LDS loading buffer (NuPAGE, Invitrogen) and boiling the samples at 95 
°C for 5 min prior to loading the samples on a 12% BisTris SDS polyacrylamide gel 
(NuPAGE, Invitrogen). The tips used for loading as well as the electrophoresis chamber filled 
with the running buffer were warmed to 80 °C in order to prevent precipitation of the 
guanidine hydrochloride while loading. After gel electrophoresis, immunoblotting was 
performed as described above. 
Statistical analysis 
For Figure 11, P-values were calculated with a one-sample T-test comparing ID50 difference 
to control (COCSBH from untreated cultures harvested after 42 DPI). For Figure 12, Figure 
14, Figure 17 and Figure 18 statistical differences were computed to compare each set of 
biological replica to the control COCSBH using a one-way ANOVA with Tukey’s multiple 
comparison test. For Figure 25, Figure 26 and Figure 27 (SCEPA), proportion of negative 
wells over dilutions was compared between drugs using a Mantel-Haenszel Chi-square test 
with a Bonferroni-Holm correction. Confidence interval for common odds ratio is given in the 
respective tables for non-significant comparisons. For Figure 29 (bioassay in tga20 mice), 
survival curves were compared using a Log-rank (Mantel-Cox) test. For Figure 30 and Figure 
31 (MPA), technical quadruplicates were compared for each individual sample using a T-test. 
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In Figure 30, the overall effect of individual LCPs was investigated by comparing a group of 
four concentrations of each individual LCPs using a post-Hoc T-test for analysis of variance. 
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PART II: PRION STRAIN TYPING USING LCPs 
Introduction 
The first idea of my thesis project was to adapt prion strain discrimination with LCPs in the 
POSCA. Since prion aggregates can readily be observed in COCS after three weeks, prion 
strain discrimination can potentially be performed in a very fast manner while reducing the 
number of animals to be used for experiments. In addition, the reduced time-scale for 
generation of successive passages of prion inocula in COCS would also enable the study of 
strain adaptation using the POSCA. Furthermore, a phenomenon called “prion strain 
competition” has been reported (Schutt and Bartz, 2008). The POSCA may enable the 
investigation of prion strain competition by inoculation of COCS with different prion strains 
and discrimination of strain-specific aggregates with LCPs. To that effect I have dedicated a 
large effort to the development of a protocol for staining COCS with LCPs and subsequent 
spectral analysis of prion strains. This has successfully led to the discrimination of mouse-
adapted prion strains in COCS on the basis of the spectral signature of prion aggregates. In 
addition, I have observed that different prion strains replicating in COCS yield aggregates 
with subtle differences that are generally not obvious in brain sections from prion-inoculated 
mice, such as deposition pattern and morphology of aggregates. These differences may arise 
specifically in the cerebellar environment and may provide a new mean of discriminating 
prion strains. 
Spectral profile of mouse-adapted prion strains in vivo and in vitro 
I used a panel of mouse-adapted prion strains that have been largely described in the literature 
including ME7 (Zlotnik and Rennie, 1963; Bruce, 1993; Bruce et al., 2002; Bruce, 2003), the 
mouse-adapted goat prion strains 79A (Bruce, 1993) and 139A (Chandler and Fisher, 1963) as 
well as a natural sheep scrapie isolate that was passaged in mice in our lab, MSS (for mouse-
passaged scrapie) and the sheep-derived (Chandler) mouse-adapted prion preparation RML 
(characterized in (Büeler et al., 1993)) (RML6: passage 6, performed in our lab). In addition, I 
used the mouse-adapted BSE strain 301C (Bruce et al., 1994). COCS were inoculated and 
cultured for 35 DIV (Figures 36 and 38A) or 56 DIV (Figures 39 and 40). In parallel, I 
investigated in a similar manner the prion strains 22L, 79A, 139A, ME7, 135X, MSS and 
301C in wild-type (WT) (not shown) and tga20 mice (Figure 37 and 38B) by staining cortical 
cryosections of terminal mice with PTAA as described by Sigurdson et al. (Sigurdson et al., 
2007). The RML strain was omitted from the in vivo part of the analysis because PTAA-
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stained RML prion aggregates cannot be observed in cryosections of terminal tga20 mice 
(Sigurdson et al., 2007), although they are abundant in COCS. The isolate 135X (described by 
Prof. Jean Manson as a variant of the strain ME7) was included as well as the 22L isolate 
(Bruce, 1993). Staining with PTAA was performed and spectral analysis of prion aggregates 
from COCS or mice inoculated with the different prion isolates revealed different spectral 
signatures: the wavelength with the maximal intensity of fluorescence was shifted from 10 to 
20 nm in COCS (Figure 36) and about 10 nm in tga20 mice (Figure 37). These spectral 
differences reveal structural differences between aggregates from different prion strains.             
In addition, the overall shapes of the curves were different: distribution of fluorescence 
intensity between 510 and 610 nm was different for aggregates of different prion strains 
(Figure 36 and 37). This may reveal spectral differences between aggregates or/and 
contribution of the background (PTAA bound to various entities within tissue, such as DNA 
and other) to the measured spectra. The latter may result from the fact that the underlying 
tissue stained with PTAA emits light between 510 and 610 nm. As different prion isolates are 
expected to provoke prion-induced neurodegeneration to variable extents, it is possible that 
differences in this region of the spectrum reveal the extent of cell death. For this reason I 
chose to perform the first part of this analysis by plotting the ratios of light emitted at 517 nm, 
685 nm and Emax. It can be appreciated in Figures 36 and 37 that the contribution of the 
background is the highest between approximately 530-610 nm and that the most obvious 
differences between spectra, with low background contribution is around 685 nm.                 
These differences are close to the discriminatory sensitivity of the SpectraCube, the machine 
used for spectral acquisition (10 nm) and some aggregates had a similar maximal emission 
(Emax) even while displaying overall different spectral curves. For this reason I performed 
spectral acquisition on a large number of aggregates (n = 5-8) from several individual COCS 
(n = 5-6) or mice (n = 3-4) (Figure 36-38). It readily appears in Figures 36 and 37 that spectral 
differences between PTAA-stained aggregates from different prion strains are more evident in 
COCS than in brain cryosections from terminal mice. This is even more obvious in the ratio 
plots (Figure 38). 
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B 
Figure 36: Spectral signature of aggregates from six prion strains in vitro after 35 DIV. 
(A) Fluorescence emission at 510 to 800 nm from 5 to 8 aggregates of the prion strains RML, 79A, 
139A, ME7, MSS and 301C in vitro. For each aggregate fluorescent emission was acquired from 9 
regions of a spectral image and averaged. Spectra from aggregates were acquired in 5 to 6 PTAA-
stained COCS (prepared from tga20 mice) per strain. Staining of tissue was performed after 35 
DIV. CD1: background spectrum from a COCS exposed to non-infectious BH from a CD1 mouse 
and PTAA-stained after 35 DIV. 
(B) Average fluorescence emission from aggregates shown in (A). 
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Figure 37: Spectral signature of aggregates from seven prion strains in vivo. 
(A) Fluorescence emission at 510 to 800 nm from 4 to 8 aggregates of the prion strains 22L, 79A, 
139A, 135X, ME7, MSS and 301C in vivo. For each aggregate fluorescent emission was acquired 
from 9 regions of the spectral image and averaged. Spectra from aggregates were acquired in 
PTAA-stained cortical cryosections from 3 to 4 tga20 mice per strain. CD1: PTAA-stained cortical 
cryosection from a tga20 mouse inoculated with non-infectious BH from a CD1 mouse. 
(B) Average fluorescence emission from aggregates shown in (A). 
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One technical problem of the analysis of prion aggregates in COCS is the impossibility of 
obtaining preparations with the same thickness, because COCS are undergoing 
neurodegeneration to variable extents during culturing and cannot be cut into thinner sections. 
As a result, the contribution of the background to the spectral signature of aggregates from 
different prion strains in COCS induces high variability between measurements for one prion 
strain and possibly differences between strains that are due to variable contribution of the 
background and not to structural differences of aggregates. As prion aggregates are growing 
into larger entities with more intense fluorescence during the course of replication I repeated 
the analysis in COCS with prolongating the culturing period until a total of 56 DIV (Figure 39 
and 40). This resulted into larger aggregates with more intense PTAA-fluorescence (about 
two fold). In addition, more profound neurodegeneration of COCS after 56 DIV contributed 
to decrease the intensity of the background and possibly to make it more homogenous 
between COCS infected with different prion strains. For these reasons I chose to include 
background differences in this analysis by plotting the ratios at 569nm/685nm and 
569nm/Emax. Of note, differences around 569 nm are probably not due only to the 
contribution of the background but also to structural differences between aggregates, as the 
entire curves are shifted between strains. Figure 40 shows that measurements of fluorescence 
from PTAA-stained aggregates from five mouse-adapted prion strains segregate into five 
Figure 38: Ratio plots from spectra shown in Figures 36A and 37A. 
(A) Ratio plot of spectra from Figure 36A (prion strains in vitro). For easier comparison between 
assays only a subset of strains (MSS, ME7, 301C, 139A and 79A) is shown. 
(B) Ratio plot of spectra from Figure 37A (prion strains in vivo). 
A B 
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homogenous and separated groups. Of note, these five groups also segregate into three 
groups: the mouse-adapted scrapie prions (RML, 22L), the mouse-adapted goat prions (79A, 
139A) and the mouse-adapted bovine prions (301C). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Spectral signature of aggregates from five prion strains in vitro after 56 DIV. 
Fluorescence emission at 510 to 800 nm from 4 to 13 aggregates of the prion strains 22L, 79A, 
139A, RML, and 301C in vitro. For each aggregate fluorescent emission was acquired from 9 
regions of a spectral image and averaged. Spectra from aggregates were acquired in 5 to 6 PTAA-
stained COCS (prepared from tga20 mice) per strain. Staining of tissue was performed after 56 
DIV. CD1: background spectrum from a COCS exposed to non-infectious BH from a CD1 mouse 
and PTAA-stained after 56 DIV. 
Figure 40: Ratio plots from 
spectra shown in Figure 39. 
Ratios 569/685 and 569/Emax 
from Figure 38. 
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To further investigate the spectra of prion aggregates I analyzed the evolution of the spectra 
from aggregates of the ME7 prion strain in vivo and in COCS after 35 or 56 DIV (Figure 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It can be appreciated in Figure 41 that the spectra of ME7 aggregates in vivo have a stronger 
red component than in COCS at 35 or 56 DIV. In addition, spectra of ME7 aggregates in 
COCS have more green component and further shift towards more green fluorescence during 
the course of culturing. The maximal emission was also shifted towards green light.                        
It is unlikely that these differences are due to the evolution of the background during culturing 
as the background may only decrease during the course of the experiment (due to cell death) 
and would therefore rather decrease the green component of the spectra in COCS. 
Heterogeneity of fluorescent spectra was stronger in COCS at 35 DIV than after 56 DIV. This 
was probably due to the facts that (1) aggregates at 56 DIV are larger and therefore emit 
stronger fluorescence and (2) background of the surrounding tissue is lower than at 35 DIV. 
Figure 41: Spectral signature of aggregates from a prion strain in vivo or in vitro. 
Fluorescence emission at 510 to 800 nm from 3 to 7 aggregates of the ME7 prion strain in cortical 
cryosections from a tga20 mouse or in COCS after 35 or 56 DIV. For each aggregate fluorescent 
emission was acquired from 9 regions of a spectral image and averaged. CD1: background 
spectrum from a COCS exposed to non-infectious BH from a CD1 mouse and PTAA-stained after 
56 DIV. Note: the background in cortical cryosections from a non-inoculated tga20 mouse is 
similar to the background in COCS from tga20 mice. 
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Finally, the structure of prion aggregates from ME7 evolved during the course of culturing of 
COCS towards entities that emit more green-shifted fluorescence. 
Additional features of prion strains in COCS 
During the course of this work, several unexpected observations were made. Firstly, prion 
aggregates from different strains appeared to grow either with a diffuse (RML, 22L, 79A, 
139A) or focal morphology (ME7, MSS, 301C). Occasionally RML appeared to yield also 
some focal aggregates (Figure 42, lower left panel) and ME7 some fibrillar structures. Figure 
42 shows as an example aggregates from RML and ME7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surprisingly, the strains with diffuse aggregates were also the strains that were yielding more 
PK-resistant material after 35 DIV, presumably growing faster than strains yielding very little 
PK-resistant material at the same time point (Falsig et al., 2008). The observations made in 
this study support this view: pictures from LCP-stained COCS show very few focal 
aggregates in COCS infected with ME7 or MSS, whereas COCS infected with RML, 22L, 
79A, 139A had abundant diffuse aggregates covering the entire surface of the slices (most 
abundant in the area of the Purkinje cell layer). COCS infected with 301C yielded amount of 
Figure 42: Morphology of aggregates from prion strains in COCS. 
Diffuse/focal morphology of RML aggregates (left panels) or focal morphology of ME7 aggregates 
(right panels). Upper panels: an entire cerebellar slice photographed with a 5x objective. Lower 
panels: granular layer photographed with a 40x objective. Lower left panel, PTMI: this LCP stains 
cell nuclei in green, showing the morphology of the different cells composing the different layers 
of the cerebellum. In all pictures fluorescent light was separated into green channel (LCP bound to 
various components of the tissue) and red channel (LCP bound to prion aggregates). The objects 
emitting strong green fluorescence in the upper left panel are artefacts originating occasionally 
from the culturing process (agarose, dust and other). 
diffuse 
focal 
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PK-resistant material intermediate to the two above-described groups and had more abundant 
aggregates in microscopy images than ME7 and MSS. 
Another interesting observation is the preferential, strain-dependent deposition of aggregates 
in particular areas: Figure 42 shows the deposition of ME7 aggregates mainly near the 
cerebellar sulci (upper right panel). In addition the occasional focal aggregates of RML were 
systematically located near the sulci. Deposition of fibrillar aggregates from RML, 22L, 79A 
and 139A started at in the Purkinje cell and granular layers as shown by staining performed at 
21 DPI (Figure 43) and progressively extended towards the molecular layer for ultimately 
covering the entire slices.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aggregates from 301C had a predominantly focal morphology; however, unlike ME7 and 
MSS, the aggregates were randomly distributed throughout the tissue (not shown). 
Interestingly, slices from 7 day-old mice yielded more abundant prion accumulation than 
slices from 14 day-old mice (Figure 44 and Figure 45), suggesting that prion replication is 
enhanced during phases of intense cell replication and/or migration or by cellular interactions. 
Figure 43: Deposition of prion aggregates in COCS. 
Diffuse RML aggregates at 21 DPI. IB4 stands for isolectin B4 and stains microglia and blood 
vessels. Scale bar: 200 µm. 
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However, the deposition pattern was more precise in slices from 14 day-old mice, probably 
linked with achieved organisation of the cerebellar tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Accumulation of prion aggregates in COCS prepared from 7 or 14 days old pups. 
RML aggregates at 35 DPI in PTAA-stained slices from 7 day-old mice (left panel) or 14 day old 
mice (right panel). Pictures were taken at a 10x magnification. Red fluorescence corresponds to 
PTAA bound to prion aggregates; green fluorescence corresponds to PTAA bound to various 
components of the tissue. 
 
 
Figure 45: Accumulation of 
RML prions in COCS 
prepared from 7 or 14 days 
old pups. 
Immunoblots showing PK-
resistant material at 35 DPI in 
COCS from 7 days old mice 
(third lane: tga20 RML, 7 d.o.) 
or 14 days old mice (seventh 
lane: tga20 RML, 14 d.o.). 
tga20 mock: uninfected COCS. 
First lane: RML BH undigested, 
10 mg. Aliquots of 20 mg 
protein were digested with PK 
to remove soluble PrP and 
loaded to the gel. The anti-PrP 
antibody POM1 was used for 
the detection. Molecular sizes 
are indicated in kDa.  
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DISCUSSION 
Spectral profile of mouse-adapted prion strains in vivo and in vitro 
Although the aim of this work was to point out spectral differences that are linked with 
structural differences of aggregates, it is difficult to avoid the contribution of the background 
tissue to the analyzed spectra. However, the extent of contribution of the background reflects 
the extent of prion-induced neurodegeneration, which is a parameter used in vivo to 
discriminate prion strains and may therefore strengthen the potential of PTAA-stained COCS 
for discriminating prion strains. Sigurdson et al. discriminated mouse-adapted prion strains 
originating from different species (cervid, ovine and bovine prions) (Sigurdson et al., 2007). 
The present analysis further confirms the efficiency of PTAA for discriminating prion strains 
originating from different species (caprine, ovine and bovine prions) on the basis of the 
structure of the aggregates and possibly also on prion-induced neurodegeneration. 
Aggregates from the ME7 strain had different spectra in COCS at 35 or 56 DIV or in vivo.            
Of note, these spectra evolved during the course of culturing in COCS from red-shifted (at 35 
DIV: closer to spectra of ME7 aggregates in vivo) towards green-shifted aggregates.                        
It is possible that ME7 exists in vivo as an ensemble of prion aggregates with heterogenous 
quaternary structures and that the simplified in vitro-cultured cerebellar environment provides 
an advantage to fewer prion forms that prevail after a certain culturing time. It is also possible 
that the artificial in vitro-cultured cerebellar environment enables strain cloning (isolation of a 
prion “substrain”) or even the generation of a new strain. In conclusion, it seems that prion 
aggregates from the ME7 strain (and possibly from other strains) may have a different 
structure in in vitro-cultured cerebellar tissue than in cortical tissue from terminally-sick mice. 
Finally, spectral analysis of prions aggregates from different strains using monodisperse LCP 
preparation such as H7A, a heptameric and pFTAA, a pentameric version of PTAA, showed 
the potential of new generations of LCPs to increase the resolution of this method as spectral 
differences between strains were more marked than with PTAA (data not shown). 
Additional features of prion strains in COCS 
The prion strains investigated in this work can be discriminated into two groups according to 
the abundance of PK-resistant material previously observed on WB at 35 DPI: the fast 
replicating strains RML, 22L, 139A and 79A and the slow replicating ME7, MSS and 301C. 
The same two groups harbour prion aggregates with distinct morphologies, respectively 
diffuse or focal PTAA-stained prion deposits. In addition these strains yielded aggregates with 
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at least three different deposition patterns (location in the molecular layer, sulci or random), 
which may provide an additional way of classifying prion strains and suggests a link between 
localization of deposits and cell types present in different locations of the tissue. 
OUTLOOK 
This work proposes spectral analysis of LCP-stained prions in COCS as a new tool for the 
characterization of prion strains on the basis of the structure of strain-specific PrP aggregates. 
Furthermore the replication rate of prion strains and the morphology and deposition pattern of 
prion aggregates in COCS may be used to generate a new method for prion strain 
classification. In addition these differences may help pointing out the involvement of different 
cell types in prion strain replication. Finally, this work may initiate follow-up projects for 
investigating the phenomena of prion strain adaptation and prion strain competition. 
MATERIAL AND METHODS PART II 
Preparation of CD1 and RML6 crude brain homogenate 
20% wt/vol RML6 or CD1 brain homogenates in 0.32M sucrose in PBS were prepared by 
three runs in a PreCellys tissue homogenizer with cooling on ice between each run. Protein 
concentrations of RML6 or CD1 brain homogenates were determined using the bicinchoninic 
acid assay (Pierce) and normalized to 1 mg/ml total protein with 0.32M sucrose in PBS. 
Preparation of LCP stock solutions 
The synthesis of the different LCPs has been described elsewhere (Ding et al., 2000). 
Lyophilized LCPs were resuspended in pure water (B.Braun, Melsungen AG) and stock 
solutions at a concentration of 1 mg/ml were prepared and stored at 4°C, protected from light. 
Serial dilutions of the LCPs were prepared in pure water. For PTAA I used a stock with a 
concentration of approximately 3 mg/ml. This stock was the same as used for the publication 
from Sigurdson et al. (Sigurdson et al., 2007). 
PTAA staining and slides preparation 
PTAA staining of COCS was performed directly on the tissue still sitting on the culture 
membrane and then transferred to a glass slide. First, cultures were washed twice with 5 ml 
PBS and fixed with pre-cooled (-20°C) 100% ethanol for 10 min at RT. Cultures were rinsed 
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twice for 15 min in 5ml PBS and staining with LCPs was performed as described in 
(Sigurdson et al., 2007). The PTAA of PTMI stocks were diluted 1:100 in PBS. After rinsing, 
tissue transfer to the glass slide was performed as follows: excess PBS was carefully removed 
with a pipet to avoid the cut membrane to fold and membrane was cut with a scalpel blade 
and detached with a tweezer. Membrane was placed upside-down on a glass slide moistened 
with a drop of PBS. Excess PBS was removed with a tissue and glass slide was left to dry 
under a laminar flow until membrane was almost completely dry (appears then white: tissue 
attaches to the membrane). PBS was added on top of the membrane for 1 min to allow tissue 
to detach and then membrane was peeled off with a tweezer. Tissue was mounted with 
Fluorescent Mounting Medium (Dakocytomation) and slides were sealed with nail polish and 
decontaminated for 2 h with 2 M NaOH. 
Spectral acquisition 
I recorded spectra with a Zeiss Axioplan 2 microscope fitted with a Spectraview 4.0 (Applied 
Spectral Imaging) and a Spectra-Cube (interferometrical optical head SD 300) module with 
cooled charge-coupled device (CCD) camera, through a 405/30 nm (LP470) or a 470/40 nm 
(LP515) bandpass filter. The data were processed with SpectraView 3.0 EXPO. I collected 
spectra from LCP-stained PrP aggregates (8 individual spots for each sample) and other 
fluorescent entities.  
Preparation of slice culture homogenates 
Tissue was harvested in PBS and homogenized according to Falsig et al in PBS. Protein 
concentration was determined using the bicinchoninic acid assay (Pierce) and normalized to 1 
mg/ml total protein with PBS. 
Proteolysis of COCSBH and Western blot analysis 
PrPSc was detected by limited proteolysis with proteinase K (PK) (Roche) and analysed by 
Western blotting. 20 µg protein aliquots were digested with 25 µg/ml PK in lysis buffer 
containing 0.5% wt/vol sodium deoxycholate, 0.5% vol/vol Nonidet P-40 and 10% vol/vol 
PBS for 60 min at 37°C and rotating at 700 rpm on a thermoshaker in a total volume of 20 µl. 
This condition allowed specific detection of PrPSc. PK digestion was terminated by adding 6.7 
µl of 4x LDS loading buffer (NuPAGE, Invitrogen) and boiling the samples at 95 °C for 5 
min. 20 µl of the samples were separated on a 12% Bis-Tris SDS polyacrylamide gel 
(NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. Membranes were blocked 
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with 5% wt/vol Topblock (Fluka) in Tris-buffered saline supplemented with Tween (150 mM 
NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) and incubated with POM1 (Polymenidou 
et al., 2005) mouse IgG1 antibody to PrPC (anti-PrPC) (200 ng/ml) as primary antibody. Horse 
radish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, Zymed) was used as a 
secondary antibody. The blots were developed using SuperSignal West Pico 
chemiluminescent substrate (Pierce) and detected in a LAS3000 system (FUJI). 
Immunohistochemistry 
For immunocytochemistry of in vitro material, the organotypic slice cultures were washed 
twice in PBS and fixed in 4% formalin overnight at 4 °C. Membrane inserts were washed and 
incubated for 1 h in blocking buffer (0.05% vol/vol Triton X-100 and 3% vol/vol goat serum 
dissolved in PBS) and incubated with the primary antibody diluted in blocking buffer at 4 °C 
for 3 days. The ALEXA488-conjugated mouse antibody IB4 (Isolectin B4, 1 μg ml-1, 
Molecular Probes) was used for staining microglia and counterstained with 4,6-diamidino-2-
phenylindole (dapi) (1 µg ml–1). Additional staining with PTAA was performed and sections 
sitting on their culture membrane were transferred on glass slides (with tissue facing up, 
unlike for spectral analysis). Images were recorded on a fluorescence microscope (BX-61, 
Olympus) equipped with a cooled black/white CCD camera. 
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PART III: COLLABORATIVE WORK 
Humanized mice project 
My activities as a Research Assistant included participation to the elaboration of a model of 
transgenic mice lacking B and T cells (Cγ-/-RAG2-/-) which immune system was reconstituted 
with human embryonic stem cells. This work was performed in a collaborative framework 
with PD Dr. Heikenwalder and Dr. Hayback. The main goal of this project is to investigate 
peripheral prion pathogenesis of human prions. My activities included negotiation of written 
consents for donation of placental tissue, extraction of blood from placenta, purification of 
human stem cells, analysis of cells and blood from reconstituted mice with FACS analysis and 
reconstitution, inoculation with human prions (sCJD) and housing of mice as well as, 
dissection and tissue analysis by WB of prion-inoculated humanized mice (Figure 46).             
My work has notably helped obtaining high efficiency of engraftment of human CD34+ cells 
in Cg-/-RAG2-/- mice (Figure 46). “Humanized“ mice showed a high degree of CD45+ cells in 
peripheral blood as well as human lymphocytes in white pulp follicles of spleens and 
mesenteric lymph nodes (MLNs) (data not shown). Interestingly, the degree of CD19+ cells in 
peripheral blood was very high at the age of 8-16 weeks and declined over time (data not 
shown). Importantly, after inoculation with human prions (sCJD 129MM), spleens and MLNs 
do not show PK-resistant material at 30 DPI (data not shown). However, PrPSc can be 
detected by WB analysis in spleen at 60 and 90 DPI (data not shown) and at 120 DPI (Figure 
48A). Optimization by me of the protocol for enrichment for human prions from spleen 
homogenates of these mice has been necessary for obtaining the results in Figure 48A. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: Inoculation scheme. 
After birth, Cg-/-RAG2-/- newborn mice are irradiated. After the second irradiation round, CD34+ 
cells are inoculated intra-hepatically. After assessment of engraftment with hu CD45+ cells by 
FACS analysis of peripheral blood, human prions (sCJD) are inoculated intra-peritoneally. After 
various time points organs are collected for further analysis. 
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Figure 48: PK-resistant material in sCJD prion-infected humanized mice 
Immunoblots of spleens from (A) sCJD-inoculated humanized mice and (B) CWD-inoculated humanized 
mice at 120 DPI. Spleens are homogenized in PBS. Sodium phosphotungstic acid precipitation is used to 
concentrate PrPSc from 500 µl spleen homogenate (lanes 3-9). The resulting pellet undergoes PK digestion 
and is loaded on a SDS-Gel (12%). The nitrocellulose membrane is probed with 3F4 (anti-human PrP 
antibody). SPIKE: 120 µg sCJD BH (from a terminally sick patient) in 500 µl Cγ-/-RAG2-/- spleen 
homogenate (10%). sCJD BH: 40 µg (-PK) or 80 µg (+PK) sCJD BH (from a terminally sick patient). 
Molecular sizes are indicated in kDa.  
 
Figure 47: Control of efficiency of engraftment with CD34+ cells. 
FACS analysis for human CD45-APC+ cells in peripheral blood from reconstituted mice at 6-12 weeks post 
reconstitution. Upper panels: Gate for living cells isolated from blood. Lower panels: Living cells gated for 
human CD45. Efficiency of engraftment (percentage of hu-CD45+ cells) shows a variation (e.g. 34.4%, 
25.7%). Approximately 70% of all mice have an engraftment larger than 5%. Cg-/-RAG2-/- non reconstituted 
mice analyzed as negative controls show a negligible background (e.g. 0.47%). SSC = sideward scatter. FSC 
= forward scatter. Human CD45 is used as a panleucocytic marker (leukocyte common antigen). 
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OUTLOOK 
Further analysis by histoblot and transmission of spleen homogenates will validate our results. 
Of note, mice inoculated with BH pooled from several cervids that succumbed to CWD 
(homogenate kindly provided by Dr. C.J. Sigurdson) do not show PK-resistant material at 90 
DPI in spleens (Figure 48B) neither in MLNs (data nor shown). Mice challenged with BSE 
prions also failed to replicate prions (data not shown). 
MATERIAL AND METHODS PART III 
Extraction of embryonic stem cells from cord blood 
A mixture of cord blood and anticoagulant was distributed in 50 ml Ficoll tubes (50 ml Falcon 
with filter and 15 ml Ficoll briefly centrifuged at 300g) using PBS to adjust volumes. About 
20 ml undiluted blood was poured in each Ficoll tube. Tubes were centrifuged for 20 min at 
600g, RT, without brakes to avoid disturbance of the white blood cell interface formed during 
centrifugation. SN was aspirated and then cells of interest were isolated including liquid up to 
the filter. This mixture was then dispatched to new 50 ml Falcon tubes, pouring 15 ml per 
tube and adding washing buffer (PBS supplemented with 2mM EDTA). Centrifugation (150g, 
10 min, RT) to get rid of thrombocytes, SN was aspirated and cells were pooled and diluted to 
50 ml with washing buffer. At that point a 30 µl aliquot was set aside for cell counting. After 
another round of centrifugation (300g, 7 min, RT) SN was aspirated and cells were 
resuspended in MACS buffer (PBS supplemented with 2mM EDTA and 0.5% v/v BSA) and 
supplemented with FCR-blocker (Miltenyi Biotech GmbH) and antibody-coupled beads 
(Miltenyi Biotech GmbH) (300 µl MACS buffer, 100 µl FCR-blocker and 100 µl beads per 
100 mio cells) and incubated for 30 min at 4°C in a fridge. After this point, only cold MACS 
buffer was used (4°C). Cells were washed in 20 ml cold MACS buffer and centrifuged (300g, 
7 min, RT), SN was discarded. Cells were resuspended in 5 ml cold MACS buffer and kept on 
ice. Two LS columns (Miltenyi Biotech GmbH) were pre-rinsed with 3 ml MACS buffer prior 
to placement in a magnetic field (QuadroMACS magnet, Miltenyi Biotech GmbH). Cells 
were applied to the first column and non-target fraction (NTF) was collected in a 50 ml 
Falcon tube. Column was washed 3 times with 3 ml MACS buffer while non-target fraction 
was collected in the 50 ml Falcon tube. Column was then placed in a 15 ml Falcon tube, away 
from the magnetic field, and target fraction (TF) was flushed out using 2 times 2.5 ml MACS 
buffer. TF in the 15 ml Falcon tube was then applied to the second column in the magnetic 
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field and handled in the same manner with collecting NTF in the 50 ml Falcon tube. Finally, 
TF was flushed out from the second column into a 15 ml Falcon tube using 3 ml MACS 
buffer. Aliquots were taken from both fractions (50 µl from TF, 200 µl from NTF) for cell 
counting and FACS analysis. TF and NTF were centrifuged (300 g, 7 min, RT), resuspended 
in freshly prepared freezing medium (90% v/v Foetal Calf Serum, 10% v/v DMSO) and 
aliquoted (TF: 1.2 mio cells in 1 ml, NTF: 30-40 mio cells in 1 ml). Tubes were placed in a 
freezing box filled with isopropanol and stored in a fridge for 60 min and then in a -80°C 
freezer overnight. Tubes were then transferred to a liquid nitrogen tank for longer storage. 
Cell staining for FACS analysis 
TF was stained as follows: 20 µl TF, 30 µl FACS buffer (PBS supplemented with 2 mM 
EDTA and 0.1% w/v sodium azide), 1 µl CD34-APC, 1 µl CD3-PE. NTF was stained as 
follows: 50 µl NTF, 50 µl FACS buffer, 2 µl CD34-APC, 2 µl CD3-PE or left unstained: 50 
µl NTF, 50 µl FACS buffer. All aliquots were incubated for 30 min at 4 °C and washed once 
with 2 ml FACS buffer. Cell viability was briefly checked with trypan blue staining (10 µl 
TF, 10 µl trypan blue stain 0.4%, Invitrogen). If stained cells were not analyzed by FACS 
immediately (not ideal), cells were fixed as follows: cells were resuspended in 1 ml FACS 
buffer supplemented with 0.5% v/v paraformaldehyde (PF), centrifuged (300 g, 3 min, RT), 
resuspended in 150 µl FACS buffer and stored overnight at 4°C in the dark. Cells obtained 
from tail blood from humanized mice were stained as follows: 4-5 drops of tail blood were 
collected in 2 ml FACS buffer and centrifuged (300 g, 7 min, RT). SN was aspirated and cells 
were stained with a mastermix (50 µl mastermix per pellet) prepared with human CD45-APC 
(human lymphocytes), CD4-FITC (helper T cells) and CD19-PE (B cells) (each Ab diluted 
1:20 in FACS buffer). Samples were vortexed and incubated for 30 min at 4°C in the dark. 1 
ml BD FACS lysis solution was added, samples were vortexed and incubated for 10 min at 
RT in the dark. Samples were washed twice with 2 ml FACS buffer and centrifuged (300 g, 7 
min, RT). SN was removed until about 100 µl was left in the tube and cells were resuspended 
with FACS buffer. FACS analysis was performed until about 20,000 events were recorded. 
Isolation of DNA from NTF or whole blood 
Isolation of DNA from either NTF or whole blood obtained from humanized mice was 
performed using a DNA isolation kit from QIAGEN according to the manufacturer’s 
instructions. DNA purity was checked in a spectrophotometer and samples were handed over 
                    RESULTS
 _____________________________________________________________________ 
89 
 
to Prof. Zimmermann (University Hospital, Zürich) for sequencing of the region of the prnp 
gene containing the 129 codon. Mice engrafted with stem cells originating from a patient 
harbouring the 129MM phenotype are ideal candidates for exposure to human prions. 
Reconstitution of newborn mice with human stem cells 
Frozen aliquots of human stem cells were thawn at 37°C in a water bath and centrifuged (300 
g, 5 min, RT). SN was removed, leaving about 100 µl and cells were resuspended in 1 ml 
PBS. Cells were centrifuged (300 g, 5 min, RT) and SN was removed, leaving about 50 µl. 
Cells were resuspended in PBS to obtain about 100-200 mio cells per 30 µl. 30 µl was 
inoculated in the liver of irradiated newborns from Cγ-/-RAG2-/- mice. Mice were housed for 
6-12 weeks post reconstitution prior to challenge with BSE, human or CWD prions. 
Sodium phosphotungstic acid precipitation and Western blot analysis 
Enrichment for prions was performed on organ homogenates from sacrificed mice using a 
previously published protocol (Ligios et al., 2007) with the following modifications: 
1. A 5- 10% organ homogenate was used when organs were too small. 2. The final pellet was 
resuspended in 500 µl PBS and ultracentrifuged (150,000 g for 1 h at 4°C). SN was removed 
and pellet was resuspended in 50-100 µl PBS. 3. After digestion with PK (50 µg/ml) samples 
were applied to a 1.5 mm thick 12% Bis-Tris SDS polyacrylamide gel (NuPAGE, Invitrogen) 
to allow loading of up to 80 µl sample (note: blotting such a gel needs increasing transfer time 
by 1 h). Western blot analysis was performed as described above with the following 
modifications: 1. Blocking of the membrane was performed in 2% w/v BSA in TBST. 2. The 
Ab 3F4 (1:2000 in 2% w/v BSA in TBST) was used as a primary Ab with IGg2a (1:5000 in 
2% w/v BSA in TBST) as a secondary Ab. Picture acquisition was performed for 15 min in a 
LAS3000 system (FUJI). 
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APPENDIX 
Tables 
 
Table 1 
Statistical analysis of prion infectivity titres shown in Figure 11 using a Mantel-Haenszel Chi-
square test with Bonferroni correction comparing ID50 difference to control (COCSBH from 
untreated cultures harvested after 42 DPI). 
Figure 11 p-value conf. interval for c. o. r. 
untreated (21 DIV) p = 0.007 -1.71(-2.35 to -1.07) 
PPS 0.3 µg/ml p = 0.012 1.99(-2.96 to -1.03) 
PTAA 60 µg/ml p < 0.001 -3.32(-3.62 to -3.01) 
PTAA 6 µg/ml p = 0.001 -2(-2.19 to -1.81) 
PTAA 1 µg/ml p = 0.106 -0.66(-1.66 to 0.34) 
PTAA 0.1 µg/ml p = 0.695 -0.13(-1.36 to 1.10) 
PTAA 0.01 µg/ml n/a n/a 
 
Table 2 
Statistical analysis of data shown in Figure 12 using a one-way ANOVA with Tukey’s 
multiple comparison test. 
Figure 12 p-value 95% c.i. of difference 
untreated (21 DIV) p < 0.0001 -228.7(-309.8 to -147.6) 
PPS 0.3 µg/ml p < 0.0001 216.9(135.8 to 298.0) 
PTAA 60 µg/ml p < 0.0001 236.1(155.0 to 317.1) 
PTAA 6 µg/ml p < 0.0001 233.9(152.8 to 315.0) 
PTAA 1 µg/ml p < 0.0001 229.0(147.9 to 310.1) 
PTAA 0.1 µg/ml p < 0.0001 199.4(118.4 to 280.5) 
PTAA 0.01 µg/ml n/s  -46.9(-128.0 to 34.18) 
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Table 3 
Statistical analysis of data shown in Figure 14A using a one-way ANOVA with Tukey’s 
multiple comparison test. 
Figure 14A p-value 95% c.i. of difference 
untreated (21 DIV) p < 0.001 -41.79(-66.96 to -16.62) 
PPS 0.3 µg/ml p < 0.001 37.56(12.39 to 62.73) 
PTAA 60 µg/ml p < 0.001 42.94(17.77 to 68.11) 
PTAA 6 µg/ml p < 0.001 40.57(15.40 to 65.74) 
PTAA 1 µg/ml p < 0.001 35.09(9.917 to 60.26) 
PTAA 0.1 µg/ml p < 0.001 26.51(1.36 to 51.70) 
PTAA 0.01 µg/ml p = 0.450 12.11(-13.06 to 37.28) 
 
Table 4 
Statistical analysis of data shown in Figure 14B using a one-way ANOVA with Tukey’s 
multiple comparison test. 
Figure 14B p-value 95% c.i. of difference 
PTAA 60 µg/ml p < 0.05 47.70(0.65 to 94.75) 
 
Table 5 
Statistical analysis shown in Figure 17 using a one-way ANOVA with Tukey’s multiple 
comparison test. 
Fig. 17A p-values 95% c.i. of difference 
7 DIV Ns -9(-108.8 to 90.80) 
19 DIV Ns -13.86(-113.7 to 85.94) 
21 DIV Ns -23.77(-123.6 to 76.03) 
28 DIV Ns -60.36(-160.2 to 39.44) 
35 DIV p < 0.001 -205.5(-305.3 to -105.7) 
42 DIV p < 0.001 -252.8(-352.6 to 153.0) 
From 7 DIV Ns -2.11(-101.9 to 97.68) 
From 19 DIV Ns -1.26(-101.1 to 98.54) 
From 21 DIV Ns 0(-99.80 to 99.80) 
From 28 DIV Ns -0.49(-100.3 to 99.30) 
From 35 DIV Ns -0.04(-99.84 to 99.75) 
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Fig. 17B p-values 95% c.i. of difference 
7 DIV n/s 0(-38 to 38) 
19 DIV n/s -0.09(-38 to 38) 
21 DIV n/s -0.95(-39 to 37) 
28 DIV n/s -6.2(-44 to 32) 
35 DIV n/s -16(-54 to 21) 
42 DIV p < 0.001 -54(-92 to -17) 
45 DIV p < 0.001 -113(-151 to -76) 
49 DIV p < 0.001 -114(-152 to -76) 
56 DIV p < 0.001 -114(-152 to -77) 
From 7 DIV n/s -0.43(-38 to 37) 
From 19 DIV n/s 0(-38 to 38) 
From 21 DIV n/s 0(-38 to 38) 
From 28 DIV n/s -4.6(-42 to 33) 
From 35 DIV n/s -21(-59 to 17) 
42 DIV vs. from 7 DIV p < 0.001 54(16 to 92) 
42 DIV vs. from 19 DIV p < 0.001 54(17 to 92) 
42 DIV vs. from 21 DIV p < 0.001 54(17 to 92) 
42 DIV vs. from 28 DIV p < 0.01 50(12 to 87) 
42 DIV vs. from 35 DIV n/s 33(-4.5 to 71) 
   
Fig. 17C p-values 95% c.i. of difference 
7 DIV Ns 44(-174 to 261) 
19 DIV Ns 71(-146 to 289) 
21 DIV Ns 67(-151 to 284) 
28 DIV Ns 52(-165 to 270) 
35 DIV Ns 162(-55 to 380) 
42 DIV Ns 53(-165 to 270) 
45 DIV Ns 107(-110 to 325) 
49 DIV Ns 14(-203 to 232) 
56 DIV Ns 88(-130 to 305) 
From 7 DIV Ns 211(-6.6 to 428) 
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From 19 DIV Ns 196(-22 to 413) 
From 21 DIV p < 0.05 223(5.7 to 441) 
From 28 DIV Ns 189(-28 to 407) 
From 35 DIV p < 0.05 236(18 to 453) 
42 DIV vs. from 7 DIV Ns 158(59 to 376) 
42 DIV vs. from 19 DIV Ns 143(-74 to 361) 
42 DIV vs. from 21 DIV Ns 170(-47 to 388) 
42 DIV vs. from 28 DIV Ns 136(-81 to 354) 
42 DIV vs. from 35 DIV Ns 183(-34 to 400) 
Statistical analysis using a one-way ANOVA with Tukey’s multiple comparison test. Unless 
stated otherwise, time points are compared to the non-infected COCS. For 42 DIV vs. From 7 
DIV, for instance, the value obtained for COCS harvested at 42 DIV is compared to the value 
obtained for COCS harvested at 42 DIV with treatment from 7 DIV. 
 
Table 6 
Statistical analysis of data shown in Figure 18 using a one-way ANOVA with Tukey’s 
multiple comparison test. 
Figure 18 p-value 95% c.i. of difference 
CD1 untr. VS CD1 +PPS 0.3 µg/ml  n/s -41.79(-66.96 to -16.62) 
CD1 untr. VS CD1 +PTAA 60 µg/ml  n/s 37.56(12.39 to 62.73) 
CD1 untr. VS CD1 +PTAA 6 µg/ml  p < 0.01 42.94(17.77 to 68.11) 
CD1 untr. VS RML untreated p < 0.001 40.57(15.40 to 65.74) 
CD1 untr. VS RML +PPS 0.3 µg/ml n/s 35.09(9.917 to 60.26) 
CD1 untr. VS RML +PTAA 60 µg/ml n/s 26.51(1.36 to 51.70) 
CD1 untr. VS RML +PTAA 6 µg/ml n/s 12.11(-13.06 to 37.28) 
RML untr. VS RML +PPS 0.3 µg/ml p < 0.001 35.09(9.917 to 60.26) 
RML untr. VS RML +PTAA 60 µg/ml p < 0.001 26.51(1.36 to 51.70) 
RML untr. VS RML +PTAA 6 µg/ml p < 0.001 12.11(-13.06 to 37.28) 
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Table 7 
Statistical analysis of the difference between prion infectivity titre of untreated RML6 
(control) compared to LCP-treated RML6 and for pHTAA-, pFTAA- and PTAA-treated 
RML6 compared to each other (Figure 25). Differences were computed by using a Mantel-
Haenszel Chi-square test for comparing number of negative wells at each dilution (10-4 to 10-
8) of a sample in the SCEPA. 
Figure 25 µg/ml p-values conf. interval for c. o. r. 
Control to PTAA 300 p < 0.001  
Control to pHTAA 300 p < 0.001  
Control to pFTAA 300 p < 0.001  
Control to PBAT 300 p < 0.001  
Control to POMT 300 p < 0.001  
Control to POWT 300 p < 0.001  
pHTAA VS PTAA 300 p = 0.450 1.69(0.61-4.67) 
pFTAA VS PTAA 300 p = 0.005 0.13(0.03-0.50) 
pFTAA VS pHTAA 300 p = 0.001 10(2.66-37.64) 
 
Table 8 
Statistical analysis of the difference between prion infectivity titre of untreated RML6 
(control) compared to LCP-treated RML6 (Figure 26). Differences were computed by using a 
Mantel-Haenszel Chi-square test for comparing number of negative wells at each dilution   
(10-4 to 10-8) of a sample in the SCEPA. 
Figure 26A µg/ml p-values conf. interval for c. o. r. 
Control to pFTAA 900 p < 0.0001  
 300 p = 0.002 0.07(0.01-0.36) 
 150 p = 0.004 0.15(0.04-0.52) 
 75 p = 0.047 0.32(0.12-0.87) 
    
Figure 26B µg/ml p-values conf. interval for c. o. r. 
Control to PTAA 5000 p < 0.0001  
 900 p < 0.0001  
 300 p < 0.0001  
 150 p < 0.0001  
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 100 p < 0.0003 0.16(0.06-0.43) 
 10 p = 0.081 0.34(0.12-0.99) 
 
Table 9 
Infectivity titres of samples described in Figure 27A. 
Plate n°: 1 2 3 4 
Infectivity titre (logID50 x g-1): 7.91 6.83 8.05 7.80 
 
Table 10 
Comparisons between infectivity titres reported in Table 9. Differences were computed by 
using a Mantel-Haenszel Chi-square test for comparing number of negative wells at each 
dilution (10-4 to 10-8) of a sample in the SCEPA. 
Plate n°: 1 2 3 4 
1  
p < 0.001 
 
p = 0.398 
1.89(0.62-5.79) 
p = 0.826 
0.78(0.29-2.15) 
2   p < 0.001 p < 0.001 
3    
p = 0.178 
0.39(0.13-1.24) 
 
Table 11 
Infectivity titres of samples described in Figure 27B. 
Plate n°: 1 2 
PTAA (µg/ml):  0 10 
Infectivity titre (logID50 x g-1): 8.05 7.78 
 
Table 12 
Comparisons between Infectivity titres reported in Table 11. Differences were computed by 
using a Mantel-Haenszel Chi-square test for comparing number of negative wells at each 
dilution (10-4 to 10-8) of a sample in the SCEPA. 
Plate n°: 1 2 
1 
 
p = 0.551 (n.s.) 
0.58(0.17-1.92) 
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Table 13 
Statistical analysis of the difference between MPA signals for untreated CD1 brain 
homogenate (mock), LCP-treated CD1 brain homogenate, untreated RML6 (control) and 
LCP-treated RML6 (Figure 30). Differences were computed by using a T- test comparing the 
log10 RLU signals in the MPA. 
 µg/ml p-values conf. interval for mean ratio 
mock + H2O to     
mock + PTAA 0 to 300 p = 0.001 1.21(1.12-1.30) 
Control to PTAA 300 p < 0.001 8.95(6.57-12.20) 
 100 p < 0.001 6.50(4.89-8.65) 
 10 p = 0.004 1.97(1.37-2.82) 
 1 p = 0.348 1.23(0.74-2.04) 
Control to POMT 300 p < 0.001 9.80(7.21-13.33) 
 100 p < 0.001 3.27(2.30-4.67) 
 10 p = 0.015 1.75(1.17-2.63) 
 1 p = 0.374 1.15(0.81-1.62) 
Control to pHTAA 300 p < 0.001 3.14(2.25-4.38) 
 100 p = 0.007 2.21(1.37-3.55) 
 10 p = 0.057 1.49(0.86-2.25) 
 1 p = 0.737 0.95(0.69-1.32) 
Control to pFTAA 300 p < 0.001 3.79(2.66-5.41) 
 100 p < 0.001 3.86(2.57-5.80) 
 10 p = 0.003 2.39(1.56-3.68) 
 1 p = 0.028 1.55(1.07-2.25) 
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Table 14 
Statistical analysis of the difference between MPA signals for RML6 treated with different 
LCPs (Figure 30). The overall effect of individual LCPs was investigated by comparing a 
group of four concentrations of each individual LCPs using a post-Hoc T-test for analysis of 
variance. 
 µg/ml p-values conf. interval for mean ratio 
PTAA to POMT All conc. p = 0.078 1.20(0.66-1.01) 
PTAA to pHTAA All conc. p < 0.001 0.51(0.42-0.63) 
PTAA to pFTAA All conc. p = 0.017 0.79(0.64-0.97) 
POMT to pHTAA All conc. p < 0.001 0.62(0.51-0.77) 
POMT to pFTAA All conc. p = 1.000 1.04(0.78-0.85) 
pHTAA to pFTAA All conc. p < 0.001 1.53(1.24-1.89) 
 
Table 15 
Statistical analysis of samples described in Figure 31. 
 
bead 
treatment p-values 
conf. interval for 
mean ratio 
CD1+H2O to CD1+PTAA  No p = 0.339 1.08(0.90-1.31) 
CD1+H2O to CD1+H2O Yes p = 0.004 1.29(1.12-1.49) 
CD1+PTAA to CD1+PTAA Yes p = 0.024 1.24(1.04-1.48) 
RML+PTAA to RML+PTAA Yes p = 0.992 1.00(0.69-1.45) 
Control to RML+H2O Yes P = 0.274 1.10(0.91-1.32) 
 
 
 
 
 
 
